

# AKT/PKB Signaling: Navigating the Network

Brendan D. Manning<sup>1,\*</sup> and Alex Toker<sup>2,\*</sup>

<sup>1</sup>Department of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

<sup>2</sup>Department of Pathology and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, and Ludwig Center at Harvard, Boston, MA 02215, USA

\*Correspondence: [bmanning@hsph.harvard.edu](mailto:bmanning@hsph.harvard.edu) (B.D.M.), [atoker@bidmc.harvard.edu](mailto:atoker@bidmc.harvard.edu) (A.T.)

<http://dx.doi.org/10.1016/j.cell.2017.04.001>

The Ser and Thr kinase AKT, also known as protein kinase B (PKB), was discovered 25 years ago and has been the focus of tens of thousands of studies in diverse fields of biology and medicine. There have been many advances in our knowledge of the upstream regulatory inputs into AKT, key multifunctional downstream signaling nodes (GSK3, FoxO, mTORC1), which greatly expand the functional repertoire of AKT, and the complex circuitry of this dynamically branching and looping signaling network that is ubiquitous to nearly every cell in our body. Mouse and human genetic studies have also revealed physiological roles for the AKT network in nearly every organ system. Our comprehension of AKT regulation and functions is particularly important given the consequences of AKT dysfunction in diverse pathological settings, including developmental and overgrowth syndromes, cancer, cardiovascular disease, insulin resistance and type 2 diabetes, inflammatory and autoimmune disorders, and neurological disorders. There has also been much progress in developing AKT-selective small molecule inhibitors. Improved understanding of the molecular wiring of the AKT signaling network continues to make an impact that cuts across most disciplines of the biomedical sciences.

## 25 Years of AKT Signaling


Thirty years ago, Stephen Staal identified and cloned the v-Akt oncogene from the AKT8 transforming retrovirus (Staal, 1987). Four years later, three laboratories independently cloned and characterized the cellular homolog of v-AKT, a 57 kDa Ser and Thr protein kinase. Bellacosa and Tschlis used cDNA hybridization with v-AKT to clone the protein kinase and termed it c-AKT (Bellacosa et al., 1991). The Hemmings group used degenerate PCR for sequences encoding protein kinase catalytic domains to identify the kinase, which they named Related to A- and C-kinase (RAC) (Jones et al., 1991). Woodgett and Coffey used library screening and identified a protein kinase they named protein kinase B (PKB) due to the similarity with PKA and PKC (Coffey and Woodgett, 1991). We now know that there are three AKT/PKB isoforms conserved in mammalian genomes: AKT1 (PKB $\alpha$ ), AKT2 (PKB $\beta$ ), and AKT3 (PKB $\gamma$ ). AKT was propelled into the signal transduction limelight a few years later, when it was found that AKT activation occurs downstream of phosphoinositide 3-kinase (PI3K), a lipid kinase linked to cellular transformation and the insulin response (Cantley, 2004–2005).

Class I PI3K phosphorylates the 3' hydroxyl of the inositol head group of phosphoinositides, resulting in the production of the lipid second messengers PtdIns-3,4-P<sub>2</sub> (PI3,4P<sub>2</sub>) and PtdIns-3,4,5-P<sub>3</sub> (PIP<sub>3</sub>); however, downstream effectors of the PI3K products were unknown in the mid-90's. Franke, Kaplan, and Tschlis, working with PDGF receptor mutants developed by Kazanietz, showed that stimulation of cells with PDGF results in the activation of AKT in a manner that depends exclusively on the ability of PI3K to bind to the PDGF receptor (Franke et al.,

1995). Burgering and Coffey (1995), as well as the Roth laboratory (Kohn et al., 1995), used similar approaches to show that AKT is activated by growth factors in a PI3K-dependent manner. At this point, AKT was firmly established as the first bona fide effector of PI3K in cells. What remained to be elucidated is the precise mechanism by which PI3K and its lipid products activate AKT. AKT possesses a pleckstrin homology (PH) domain at its amino terminus, which Downes and Alessi initially showed can bind to PIP<sub>3</sub> (James et al., 1996). Subsequently, both PI3,4P<sub>2</sub> and PIP<sub>3</sub> were shown to directly bind to the PH domain of AKT, and PI3,4P<sub>2</sub> binding was found to induce partial activation of the protein kinase in vitro (Franke et al., 1997; Frech et al., 1997; Klippel et al., 1997).

Other landmark findings in the field were the mechanisms of termination of AKT activity and its first substrates. PI3K activity is opposed by the tumor suppressor PTEN, first cloned by the Parsons and Steck laboratories (Li et al., 1997; Steck et al., 1997) and characterized as a PIP<sub>3</sub> phosphatase by Dixon (Mae-hama and Dixon, 1998). Concomitant with the identification of AKT as a PI3K effector, much work was being undertaken to uncover the role of PI3K in insulin signaling, leading to the discovery that GSK-3 $\beta$  is a substrate of AKT in insulin-stimulated cells (Cross et al., 1995). The identification of this first substrate of AKT was also instrumental in subsequent studies to define the optimal AKT consensus phosphorylation motif (Alessi et al., 1996b), which has since facilitated the discovery of over a hundred AKT substrates linked to cell physiology and disease.

In the past 25 years, the AKT signaling field has seen remarkable expansion and discoveries that have central relevance to



**Figure 1. Molecular Mechanisms of AKT Regulation**

(A) Stimulation of RTKs or GPCRs leads to activation of PI3K, leading to PIP<sub>3</sub> production at the plasma membrane. Cytosolic inactive AKT is recruited to the membrane and engages PIP<sub>3</sub> through PH domain binding. This leads to phosphorylation of T308 and S473 by PDK1 and mTORC2, respectively, resulting in full activation. Signal termination is achieved by the PIP<sub>3</sub> phosphatase PTEN and the PP2A and PHLPP protein phosphatases. A separate endomembrane pool of active AKT likely exists that is activated through engagement of PI3,4P<sub>2</sub> through the action of the SHIP phosphatase and terminated by INPP4B. (B) The modular structure of AKT1, with position of PTMs color coded for phosphorylation (pSer/pThr/pTyr), acetylation (Lys-Ac), ubiquitylation (Lys-Ub), methylation (Lys-Me), hydroxylation (Pro-OH), glycosylation (O-GlcNac), and SUMOylation (Lys-SUMO).

products are generally considered to be obligate and rate limiting for proper AKT activation. The canonical pathway leading to AKT activation is initiated by the stimulation of receptor tyrosine kinases (RTK) or G-protein-coupled receptors (GPCR) leading to plasma membrane recruitment and activation of one or more isoforms of the class I PI3K family (Figure 1A; for a detailed review on PI3K, see Vanhaesebroeck et al. [2010]). Also important for regulation of PI3K is interaction with members of the Ras family of small GTPases (Rodriguez-Viciano et al., 1994). Class I PI3Ks predominantly phosphorylate PI4,5P<sub>2</sub>, thereby producing PIP<sub>3</sub> (Vanhaesebroeck et al., 2010), whereas the synthesis of PI3,4P<sub>2</sub> typically follows, perhaps resulting from the action of the 5'-phosphatase SH2-domain-containing inositol 5'-phosphatase (SHIP) on PIP<sub>3</sub> (Franke et al., 1997; Guilherme et al., 1996). PI3,4P<sub>2</sub> can also be synthesized by class II PI3Ks using PI4P as substrate (reviewed in Hawkins and Stephens [2016]). Although the specific PI3K isoform activated in a given cellular context may differ, the ultimate output is the same: relocalization of inactive AKT to membrane sites of PI3,4P<sub>2</sub> or PIP<sub>3</sub> accumulation via engagement of the AKT PH domain.

health and human disease. Here, we provide an update and expansion to a review from 2007 (Manning and Cantley, 2007) that provides a more network-based view of AKT signaling. We highlight the detailed mechanisms that account for AKT regulation, the key downstream branches regulated by AKT, how the AKT network is wired and integrated with other cellular signals, how this in turn influences the physiology and pathobiology of AKT, and finally, how therapeutic targeting of the AKT network can be used to treat human diseases.

**Upstream Regulation of AKT**  
**PI3K-Dependent AKT Activation**

Activation of PI3K by extracellular stimuli results in activation of AKT in virtually all cells and tissues. As such, PI3K and its lipid

strategies are generally considered to be obligate and rate limiting for proper AKT activation. The canonical pathway leading to AKT activation is initiated by the stimulation of receptor tyrosine kinases (RTK) or G-protein-coupled receptors (GPCR) leading to plasma membrane recruitment and activation of one or more isoforms of the class I PI3K family (Figure 1A; for a detailed review on PI3K, see Vanhaesebroeck et al. [2010]). Also important for regulation of PI3K is interaction with members of the Ras family of small GTPases (Rodriguez-Viciano et al., 1994). Class I PI3Ks predominantly phosphorylate PI4,5P<sub>2</sub>, thereby producing PIP<sub>3</sub> (Vanhaesebroeck et al., 2010), whereas the synthesis of PI3,4P<sub>2</sub> typically follows, perhaps resulting from the action of the 5'-phosphatase SH2-domain-containing inositol 5'-phosphatase (SHIP) on PIP<sub>3</sub> (Franke et al., 1997; Guilherme et al., 1996). PI3,4P<sub>2</sub> can also be synthesized by class II PI3Ks using PI4P as substrate (reviewed in Hawkins and Stephens [2016]). Although the specific PI3K isoform activated in a given cellular context may differ, the ultimate output is the same: relocalization of inactive AKT to membrane sites of PI3,4P<sub>2</sub> or PIP<sub>3</sub> accumulation via engagement of the AKT PH domain.

Signal termination of PI3K-PIP<sub>3</sub> signaling is primarily achieved by the phosphatase PTEN, which dephosphorylates PIP<sub>3</sub> converting it back to PI4,5P<sub>2</sub>. The initial synthesis of PI3K lipid products is observed within seconds to minutes of growth factor stimulation; exhibits a peak, generally in the first hour; and is then downregulated with a timing that depends on the cell type and stimulus (Auger et al., 1989). The transient nature of this signal is largely achieved by PTEN action combined with temporal inactivation of PI3K. While AKT is the most widely studied

effector of PI3K signaling and influences most phenotypes associated with PI3K pathway activation, it is worth noting that many other downstream effectors of PI3K exist that are activated in parallel to AKT and contribute to the subsequent cellular response (Vanhaesebroeck et al., 2010).

### Major Regulatory Phosphorylation Events on AKT

Activation of PI3K results in the phosphorylation of two key residues on AKT1, T308 in the activation, or T-loop, of the catalytic protein kinase core, and S473 in a C-terminal hydrophobic motif (Alessi et al., 1996a) (Figures 1A and 1B). Phosphorylation of both residues is required for maximal activation of the kinase. Regulation also occurs on corresponding residues in AKT2 (T309 and S474) and AKT3 (T305 and S472). The phosphoinositide-dependent protein kinase 1 (PDK1) was discovered for its ability to phosphorylate AKT1 at T308, which is required for AKT activity (Alessi et al., 1997; Stokoe et al., 1997). Relocalization of both AKT and PDK1 to membrane sites of PIP<sub>3</sub> or PI3,4P<sub>2</sub> synthesis induces conformational changes, providing access of PDK1 to AKT for phosphorylation of T308. In the inactive conformation, the AKT PH domain is inhibitory, and this “PH-in” conformation is relieved by PH domain engagement of PI3K products, resulting in a “PH-out” conformation that releases the kinase domain and allows its phosphorylation by PDK1 (Calleja et al., 2007; Calleja et al., 2009). PDK1 is also required for activation loop phosphorylation of other AGC family protein kinases (referring to those related to Protein Kinases A, G, and C), including all isoforms of the growth-factor-stimulated kinases PKC, S6K, SGK, and RSK (Mora et al., 2004); however, none of these kinases possess a PIP<sub>3</sub>-binding domain, and AKT appears to be the only obligate PIP<sub>3</sub>-dependent PDK1 target among this group (Collins et al., 2003; McManus et al., 2004).

Maximal activation of AKT requires phosphorylation of S473 in the hydrophobic motif. The primary AKT S473 kinase is the mechanistic target of rapamycin (mTOR) complex 2 (mTORC2) (Sarbasov et al., 2005) (Figures 1A and 1B). While AKT lacking S473 phosphorylation has activity, it is greatly diminished, and phosphorylation of S473 stabilizes T308 phosphorylation and the activation state of AKT (Alessi et al., 1996a; Yang et al., 2002). By analogy with PDK1, mTORC2 also phosphorylates other AGC kinases at their corresponding hydrophobic motif residues, although the corresponding motif in S6K1 (T389) is targeted by mTORC1 (Saxton and Sabatini, 2017). Also like PDK1, some targets of mTORC2 are phosphorylated constitutively (e.g., PKC), whereas others are phosphorylated only in response to PI3K signaling (e.g., AKT, SGK). The protein kinase activity of mTORC2, assayed in immunoprecipitations, is stimulated by growth factors in a PI3K-dependent manner (Huang et al., 2008; Sarbasov et al., 2005). A recent study suggested a mechanism of this regulation, indicating that a PH domain within the SIN1 component of mTORC2 serves to bind to PIP<sub>3</sub>, leading to relief of autoinhibition of mTOR kinase activity within the complex (Liu et al., 2015). PIP<sub>3</sub> binding would therefore have the dual function of relocalizing mTORC2 to membranes where AKT is being recruited, as well as relieving conformational constraints on mTOR, allowing AKT phosphorylation; however, a separate study using intracellular compartment-specific reporters concluded that PI3K activation is dispensable for mTORC2 activity on membranes (Ebner et al., 2017b). In this


model, it is the relocalization of AKT to specific membranes through its PH domain that allows mTORC2 to gain access to S473. Although earlier studies suggested that PIP<sub>3</sub> is exclusively localized to the plasma membrane, more recent reports have provided evidence for endomembrane pools of PIP<sub>3</sub> and PI3,4P<sub>2</sub> that directly contribute to AKT activation (Jethwa et al., 2015) (Figure 1A). Clearly, the molecular and spatial regulation of mTORC2 and its relationship to AKT activation remain important and active areas of investigation. Finally, the mTOR-related kinase DNA-dependent protein kinase (DNA-PK) can substitute for the activity of mTORC2 for AKT S473 phosphorylation in response to DNA damage (Bozulic et al., 2008), but the spatial nature of this regulation has not been defined.

The lifetime of active, fully phosphorylated AKT at the plasma membrane is relatively short (Calleja et al., 2007; Jethwa et al., 2015). Since phosphorylated AKT can be detected intracellularly and can phosphorylate substrates up to 2 hr post-stimulation (Kunkel et al., 2005), it is generally believed that AKT can dispense with PIP<sub>3</sub> binding once phosphorylated and in an active conformation; however, a recent study found that PIP<sub>3</sub> binding allosterically activates AKT and that dissociation from PIP<sub>3</sub> is rate limiting for AKT dephosphorylation and inactivation (Ebner et al., 2017a). In this provocative model, AKT-mediated substrate phosphorylation must be restricted to membranes containing PI3K lipid products, rather than through active AKT being released into cytosolic compartments; however, AKT phosphorylates a myriad of protein substrates with diverse subcellular localizations (Manning and Cantley, 2007). Some AKT targets localize to endomembrane surfaces (e.g., TSC2 [Menon et al., 2014; Roberts et al., 2004]), but others do not, such as nuclear-localized transcription factors (e.g., FoxO [Brunet et al., 1999]). This caveat notwithstanding, endomembranes contain PI3,4P<sub>2</sub>, and this mode of AKT regulation could represent a mechanism by which PI3,4P<sub>2</sub> and PIP<sub>3</sub> engage distinct pools of AKT (Braccini et al., 2015) (Figure 1A). This model is supported by studies on the PI3,4P<sub>2</sub> phosphatase and tumor suppressor INPP4B, the loss of which leads to elevated PI3,4P<sub>2</sub> at endosomes and activation of AKT2 (Braccini et al., 2015; Fedele et al., 2010; Gewinner et al., 2009; Li Chew et al., 2015). Restricting AKT activity to membranes where PI3K lipid products are present could serve to provide specificity and fidelity in substrate selection, as well as a mechanism of spatial segregation for specific signaling events.

Although a multitude of studies have demonstrated an obligate requirement for PI3K in activation of AKT, there are reports suggesting that AKT activation can proceed in a manner that is independent of PI3K and, presumably, phosphoinositide binding to AKT; however, whether functional AKT activation can occur in the absence of productive PI3K signaling has not been firmly established, and any such mechanism would have to be supported by clear cut evidence of PH domain release and exposure of the catalytic kinase core.

### Other Regulatory Modifications of AKT

While T308 and S473 phosphorylation are considered rate limiting and obligatory for maximal AKT activation downstream of PI3K, many other post-translational modifications have been detected and presumably serve to fine tune AKT activation, inactivation, cellular localization, or, perhaps, substrate specificity



**Figure 2. Substrates and Functions of the AKT Signaling Network**

AKT phosphorylates downstream substrates that are involved in the regulation of diverse cellular functions, including multifunctional substrates. A partial list of known substrates is shown. P indicates phosphorylation, with red and green denoting inhibitory and activating regulation, respectively.

dues—particularly, P125 and P313—thereby triggering interaction with pVHL (Guo et al., 2016).

AKT is ubiquitinated on multiple distinct Lys residues. With respect to degradative polyubiquitylation, multiple E3 ubiquitin-ligases have been shown to catalyze K48-linked ubiquitylation of AKT, thereby promoting proteasome-dependent degradation (reviewed in Chan et al. [2014]). By contrast, distinct ubiquitin ligases that couple K63-linked ubiquitin to AKT serve to regulate AKT activation. For example, various growth factors elicit activation of the TRAF6

(Figure 1B). Numerous phosphorylation sites on AKT have been mapped, and some of these have been linked to AKT function (Guo et al., 2014). T450 in a region termed the turn-motif is constitutively phosphorylated by mTORC2, occurs co-translationally, and is required for proper folding of the nascent AKT polypeptide (Facchinetti et al., 2008; Ikenoue et al., 2008). S477 and T479 in the regulatory domain can be phosphorylated in a cell-cycle-dependent manner by the cyclin A-CDK2 complex but can also be targeted, along with S473, by mTORC2 to enhance AKT activity (Liu et al., 2014). CK2 has been shown to phosphorylate S129 and increase catalytic activity (Di Maira et al., 2005), whereas GSK-3 $\alpha$ -mediated phosphorylation of T312 appears to attenuate AKT activity (Gulen et al., 2012). Many additional phosphorylation sites on AKT, including a number of tyrosine residues, have been mapped by phosphoproteomics, but the mechanisms that account for these modifications and their physiological significance are unknown (reviewed in Risso et al. [2015]; see <http://www.phosphosite.org>).

Beyond phosphorylation, various other post-translational modifications on AKT isoforms have been identified (Figure 1B). Acetylation of K14 in the AKT PH domain has been documented, and SIRT1 deacetylates this residue. K14 acetylation has been proposed to be required for AKT binding to PIP<sub>3</sub> and, therefore, membrane translocation (Sundaresan et al., 2011). The K14 residue in the PH domain seems to be functionally important for regulation, since it is modified by acetylation, ubiquitylation, and methylation, depending on the cellular conditions used. Oxidation of Cys residues in the AKT2 linker region has been reported and may provide isoform-specific regulation, since these residues are not conserved in AKT1 or AKT3 (Wani et al., 2011). Glycosylation of AKT on T305 and T312 in the catalytic core has also been reported (Wang et al., 2012). AKT is hydroxylated by the prolyl hydroxylase EglN1 (also known as PHD2) on a number of Pro resi-


(Yang et al., 2009), Skp2 (Chan et al., 2012), and NEDD4-1 (Fan et al., 2013) E3 ligases that target Lys residues in the AKT PH domain, and these modifications enhance membrane localization. Termination of this signal is achieved by the deubiquitinating enzyme CYLD (Lim et al., 2012). Finally, SUMOylation of AKT at several Lys residues, including K276, mediated by the SUMO E3 ligase PIAS, has also been reported and suggested to be involved in AKT activation (Li et al., 2013).

#### Signal Termination by AKT Phosphatases

In addition to signal termination by lipid phosphatases such as PTEN and INPP4B, two critical protein phosphatases function to directly inactivate AKT (Figure 1A). Protein phosphatase 2A (PP2A) dephosphorylates AKT T308, leading to kinase inactivation (Andjelković et al., 1996). The PP2A B55 $\alpha$  regulatory subunit can directly bind to AKT in lymphoid cells (Kuo et al., 2008), whereas the B56 $\beta$  subunit directs PP2AC to AKT in adipocytes (Padmanabhan et al., 2009). The PH domain leucine-rich repeat protein phosphatases (PHLPP1 and PHLPP2) were discovered as the physiological AKT S473 phosphatases (Gao et al., 2005). PHLPP1 and PHLPP2 dephosphorylate S473 on specific AKT isoforms (Brognard et al., 2007). Since loss of PHLPP activity leads to hyperphosphorylation of AKT, it is not surprising that PHLPP1 and PHLPP2 expression is reduced or lost in many cancers (Chen et al., 2011).

#### AKT Substrates and Functions: Key Signaling Nodes

There are well over 100 AKT substrates reported in research literature. While not all of these targets have been rigorously validated, as discussed previously (Manning and Cantley, 2007), the collective studies on AKT signaling over the years suggest a widely diverse repertoire of downstream effects in different settings stemming from its parallel regulation of multiple substrates (examples in Figure 2). In a sequence context-



**Figure 3. GSK3 Regulation and Substrate Phosphorylation**

GSK3 recognizes and phosphorylates substrates that are previously phosphorylated by a priming kinase. A partial list of known GSK3 substrates is shown. AKT's phosphorylation of GSK3 inactivates it by blocking its access to primed substrates.

### Glycogen Synthase Kinase 3


The multi-functional Ser and Thr protein kinase glycogen synthase kinase 3 (GSK3) was the first AKT substrate reported (Cross et al., 1995). The two isoforms, GSK3 $\alpha$  and GSK3 $\beta$ , share 85% sequence homology and are functionally redundant in some contexts, but isoform-specific functions have been identified in specific tissues

dependent manner, AKT directly phosphorylates protein targets of numerous functional classes, including protein and lipid kinases, transcription factors, regulators of small G proteins and vesicle trafficking, metabolic enzymes, E3 ubiquitin ligases, cell cycle regulators, and many others. AKT phosphorylates these targets on Ser and Thr residues, primarily within a minimal consensus recognition motif of R-X-R-X-X-S/T- $\phi$  (where X is any amino acid and  $\phi$  denotes a preference for large hydrophobic residues) to either activate or, more often, inhibit the function of the given protein; however, the mere existence of this motif, which can be found in thousands of proteins, does not render that protein as a bona fide AKT substrate. Factors such as accessibility of the site on the substrate, secondary interactions with AKT, and subcellular compartmentalization are also likely to contribute. In addition, a few well-established AKT substrates are phosphorylated on modified versions of this motif, including the AMP-regulated protein kinase (AMPK) and ATP-citrate lyase (ACLY), both of which have a Pro residue at the  $-5$  position, rather than the canonical Arg residue (Berwick et al., 2002; Horman et al., 2006). It is also now recognized that even the most well-established AKT substrates are not exclusively regulated by AKT, with context-dependent redundancy in substrate regulation being a prevalent feature of the signaling network (see below).

Key considerations for validating a candidate target of AKT as a bona fide substrate and the function of many established targets have been reviewed previously (Manning and Cantley, 2007). AKT isoforms have cell- and tissue-specific functions, but most prominently, AKT activation can promote cell survival, proliferation, growth, and changes in cellular metabolic pathways through its numerous downstream targets. While the AKT-mediated phosphorylation of many of its substrates has just one physiological consequence, AKT also controls key signaling nodes that subsequently regulate multiple cellular targets and functions (Figure 2). In the context of a network-based view of AKT signaling, we highlight the three best-established downstream targets of AKT, which are also key signaling nodes that integrate AKT signaling with additional cellular regulatory circuits.

(Kaidanovich-Beilin and Woodgett, 2011). Through complex formation with distinct signaling components, GSK3 participates in different signaling pathways in cells, most notably the Wnt- $\beta$ -catenin pathway. Importantly, GSK3 regulation in such pathways is believed to be independent of its regulation by growth factor signaling through PI3K and AKT. GSK3 is generally active in the absence of exogenous signals and is thus acutely inactivated upon stimulation of cells with growth factors. AKT exerts an inhibitory phosphorylation on an amino-terminal motif conserved in both GSK3 $\alpha$  (S21) and GSK3 $\beta$  (S9). The molecular nature of this regulation stems from GSK3's own substrate specificity, which includes a strong preference for phosphorylation of Ser and Thr residues that are four residues amino-terminal to a previously phosphorylated Ser and Thr (referred to as priming at the +4 position). The phosphate from the priming site on the substrate is recognized by a phosphate-binding pocket in the kinase domain of GSK3, which positions the target Ser and Thr residue for phosphorylation by the adjacent catalytic site of the kinase (Dajani et al., 2001; Frame et al., 2001; ter Haar et al., 2001). The AKT-mediated phosphorylation of GSK3 on the amino terminus creates an intramolecular pseudosubstrate that occludes the phosphate-binding pocket and inhibits substrate accessibility to GSK3 (Figure 3).

GSK3 regulates a large, functionally diverse set of direct downstream targets, most of which are inhibited or degraded upon GSK3-mediated phosphorylation (Kaidanovich-Beilin and Woodgett, 2011). As such, growth factor signaling through AKT positively regulates these targets through the inhibition of GSK3. The fact that distinct signaling pathways and protein kinases are responsible for the priming of individual GSK3 substrates adds an extra layer of complexity that allows the integrated regulation of these targets by multiple signaling inputs. The phosphorylation of some GSK3 targets involved in control of cell survival or proliferation creates a "phospho-degron" that is recognized by specific E3 ubiquitin ligases that subsequently target the substrate for proteasomal degradation. These include the prosurvival BCL-2 family member MCL-1 (Ding et al., 2007; Maurer et al., 2006; Morel et al., 2009) and the transcription factor c-Myc (Sears et al., 2000; Welcker et al., 2004), which are primed



**Figure 4. AKT-Mediated Regulation and Transcriptional Targets of FoxO Family Members**

(A) Schematic of three FoxO family members, with the three conserved AKT phosphorylation sites denoted relative to the DNA-binding domain (DBD), nuclear localization sequence (NLS), and nuclear export sequence (NES).

(B) AKT-mediated phosphorylation of FoxO leads to its binding and cytosolic sequestration by 14-3-3 proteins, thereby attenuating the expression of its gene targets, a partial list of which is shown.

FoxO proteins in the cytosol (Figure 4B). In this manner, AKT signaling suppresses the expression of FoxO targets involved in the induction of apoptosis (e.g., BIM and PUMA), cell-cycle arrest (e.g., p21 and p27), catabolism and growth inhibition (e.g., Sestrin3, MAP1LC3B, and BNIP3), and tissue-specific metabolic changes (e.g., PEPCK and G6PC) (van der Vos and Coffey, 2011; Webb and Brunet, 2014).

The highly conserved genetic relationship between AKT and FoxO family members provides definitive proof of the vital regulatory interaction between AKT signaling and suppression of the FoxO transcriptional program. This connection

was first recognized in *C. elegans*, where dauer-stage arrest induced by depletion of the two AKT isoforms (*akt-1* and *akt-2*) was completely rescued by loss of the sole FoxO family member (*daf-16*) (Paradis and Ruvkun, 1998). In mice, liver-specific ablation of *Akt1* and *Akt2* gives rise to severe hepatic insulin resistance and hyperglycemia, phenotypes that are reversed by co-deletion of the primary isoform of FoxO in the liver, *Foxo1* (Lu et al., 2012). Collectively, these studies demonstrate that the primary phenotypes caused by loss of AKT signaling in these settings are driven by sustained FoxO-mediated transcription. Thus, FoxO is the key downstream target of AKT signaling for many physiological processes (see below).


#### **Forkhead Box O Family Transcription Factors**

The Forkhead Box O (FoxO) transcription factors, comprised of FoxO1, 3, 4, and 6, control a diverse set of gene targets that are, among other responses, involved in adaptation to fasting and low insulin and IGF1 signaling (van der Vos and Coffey, 2011; Webb and Brunet, 2014). Activation of PI3K-AKT signaling leads to acute translocation of FoxO proteins out of the nucleus and attenuation of their transcriptional program (Brunet et al., 1999; Kops et al., 1999). AKT mediates this regulation through direct phosphorylation of three conserved residues on these factors (Figure 4A). Phosphorylation of the most amino-terminal site and a second site within a nuclear localization sequence (NLS) on the FoxO proteins (T24 and S256 on FoxO1) generates recognition motifs for the 14-3-3 family of phospho-binding proteins, which facilitate the export and sequestration of phosphorylated

was first recognized in *C. elegans*, where dauer-stage arrest induced by depletion of the two AKT isoforms (*akt-1* and *akt-2*) was completely rescued by loss of the sole FoxO family member (*daf-16*) (Paradis and Ruvkun, 1998). In mice, liver-specific ablation of *Akt1* and *Akt2* gives rise to severe hepatic insulin resistance and hyperglycemia, phenotypes that are reversed by co-deletion of the primary isoform of FoxO in the liver, *Foxo1* (Lu et al., 2012). Collectively, these studies demonstrate that the primary phenotypes caused by loss of AKT signaling in these settings are driven by sustained FoxO-mediated transcription. Thus, FoxO is the key downstream target of AKT signaling for many physiological processes (see below).

#### **Tuberous Sclerosis Complex 2 and mTORC1**

PI3K and AKT play an evolutionarily conserved role in promoting cell, tissue, and organismal growth downstream of growth factors such as IGF1. This regulation is primarily through the AKT-mediated activation of the protein kinase complex mTORC1, which stimulates the biosynthetic processes underlying cell growth (Saxton and Sabatini, 2017). The primary mechanism by which AKT activates mTORC1 is through the phosphorylation and inhibition of tuberous sclerosis complex 2 (TSC2, also known as tuberin) (Inoki et al., 2002; Manning et al., 2002; Potter et al., 2002), which functions within a protein complex also containing TSC1 and TBC1D7, collectively referred to as the TSC complex (Figure 5A). Through a C-terminal domain, TSC2 acts as a GAP specific for the Ras-related GTPase Rheb, thereby promoting the conversion of Rheb-GTP to Rheb-GDP (Saxton and Sabatini, 2017). In its GTP-bound form, Rheb is an essential activator of mTORC1. Thus, through its Rheb-GAP activity, the TSC



**Figure 5. Regulation of mTORC1 via the TSC Complex and Downstream Functions of mTORC1**

(A) Schematic of the TSC complex components, their regions of association (dashed lines), and AKT phosphorylation sites on TSC2. Conserved domains of unknown function and GAP, coiled-coil, and TBC domains of the components are shown.

(B) Model of signal integration by growth factors and amino acids for regulation of mTORC1. The Rag heterodimer interacts with the Ragulator and V-ATPase at the lysosomal surface, and amino acids promote mTORC1 binding to this complex. The TSC complex maintains Rheb in the GDP-bound state. Growth-factor-stimulated AKT phosphorylates TSC2, resulting in dissociation from the lysosomal surface, allowing Rheb to become GTP loaded and activate mTORC1.

(C) The PI3K-mTOR signaling pathway, depicting downstream functions and feedback regulation.

complex is a potent inhibitor of mTORC1. The AKT-mediated phosphorylation of TSC2 relieves this inhibition to activate mTORC1.

The activation state of mTORC1 is controlled in an integrated manner by largely independent signals impinging on Rheb and a second class of small GTPases called the Rags (Saxton and Sabatini, 2017). A heterodimer of Rag isoforms localizes to the cytoplasmic face of the lysosome through an interaction with a protein complex referred to as the Ragulator, which itself interacts with the lysosomal V-ATPase. Through a variety of sensing mechanisms, the guanine nucleotide-binding state of the Rag proteins is altered by amino acid availability in a manner that influences the ability of the Rag heterodimer to interact with mTORC1. In the presence of amino acids, the Rag proteins recruit mTORC1 to the lysosomal surface, where a sub-population of Rheb resides. In the absence of growth factors, the TSC complex associates with Rheb on the lysosome and maintains it in the GDP-bound state, unable to activate mTORC1 (Menon et al., 2014). Growth factor stimulation causes immediate release of the TSC complex from Rheb at this location in a manner that is dependent on AKT and its five phosphorylation sites on TSC2 (Figures 5A and 5B). Release of the TSC complex allows Rheb to become GTP loaded and locally activate mTORC1 recruited by the Rag proteins. This regulatory circuit serves as a spatial integrator of distinct signals, assuring that mTORC1 is only maximally activated when sufficient intracellular amino acids are sensed upstream of the Rag proteins and an exogenous signal from growth factors is propagated through AKT and the TSC complex.

It is also worth noting that AKT has been suggested to directly phosphorylate mTOR on S2448 (Navé et al., 1999; Sekulić et al., 2000), and this phosphorylation is frequently used as a marker of mTORC1 activation; however, subsequent studies demonstrated that S2448 is phosphorylated by S6K downstream of mTORC1 (Chiang and Abraham, 2005; Holz and Blenis, 2005), and this phosphorylation occurs on mTOR within both mTORC1 and mTORC2 (Rosner et al., 2010). Furthermore, mutation of S2448 does not appear to influence mTOR function, and its functional significance remains unknown. While mTOR phosphorylation on S2448 can correlate with mTORC1 signaling, these factors invalidate this phosphorylation as a specific marker for mTORC1 activity.

Proline-rich AKT substrate of 40 kDa (PRAS40; also known as AKT1S1) is another AKT target that is involved in mTORC1 regulation (Sancak et al., 2007; Vander Haar et al., 2007). PRAS40 is a protein of unknown function that is a non-essential component of mTORC1. AKT phosphorylates PRAS40 on T246 (Kovacina et al., 2003), and this substrate has become a reliable readout of AKT activity in cells and tissues. PRAS40 has inhibitory activity toward mTORC1 that is attenuated upon T246 phosphorylation (Sancak et al., 2007; Vander Haar et al., 2007); however, the role of PRAS40 phosphorylation in relaying the signal from AKT to mTORC1 activation remains unclear, with conflicting findings on whether loss of PRAS40 leads to growth-factor-independent activation of mTORC1 (Sancak et al., 2007; Vander Haar et al., 2007). This is in contrast to components of the TSC complex, the loss of which lead to full AKT-independent activation of mTORC1, despite PRAS40 being in the dephosphorylated state

in such settings (Sancak et al., 2007). Furthermore, insulin fails to activate mTORC1 signaling in cells lacking the AKT phosphorylation sites on TSC2, despite normal induction of PRAS40 phosphorylation (Menon et al., 2014). Thus, the TSC-Rheb circuit appears to be dominant over PRAS40 for mTORC1 regulation by Akt—at least in some settings. Interestingly, PRAS40 is also a substrate of mTORC1, and independent studies suggest that it might exert its negative regulatory effect through a substrate competition mechanism (Fonseca et al., 2007; Oshiro et al., 2007).

Through its regulation of the TSC-Rheb-mTORC1 circuit, AKT serves to link growth factor signals to a major signaling node controlling the metabolic changes that underlie cell growth (Saxton and Sabatini, 2017). mTORC1 activation serves to promote a variety of anabolic processes, such as protein, lipid, and nucleotide synthesis, while inhibiting the catabolic process of autophagy. In addition, mTORC1 is both a key downstream effector of PI3K-AKT signaling and a pathway inhibitor that exerts potent negative feedback effects on AKT activation by RTKs (Figure 5C, see below).

### Central Features of the AKT Signaling Network

Studies of the AKT signaling network using increasingly sophisticated genetic, pharmacological, cell biological, and biochemical approaches have revealed the complex wiring of this branching and looping network and its intimate regulatory links to other cellular signaling networks. These features are key to understanding signal propagation within the network, context-dependent cellular responses, and the inherent challenges of targeting the network in human diseases.

### Feedback Mechanisms

Like all signaling pathways, the PI3K-AKT pathway is subjected to negative feedback regulation to assure that stimulatory signals are sensed and relayed in a transient manner. The sheer number of distinct negative feedback mechanisms that have been identified for PI3K-AKT signaling underscore the importance of switch-like behavior for this pathway and that turning AKT signaling back off is as central to proper pathway function as turning it on. Thus, several downstream effectors of AKT signaling also exert negative regulatory inputs into AKT activation, thereby acting as rheostats that both perceive signaling through the pathway and regulate pathway activity.

Among the downstream targets of AKT signaling, mTORC1 appears to play a particularly important role in acute feedback inhibition of AKT through a variety of mechanisms (Figure 5C). It has been recognized for many years that short-term treatment with the mTORC1 inhibitor rapamycin enhances the responsiveness of AKT to RTK signaling, most notably to insulin and IGF1 (Manning, 2004). Much of this regulation has been attributed to mTORC1-dependent degradation of the insulin receptor substrates (IRS) IRS1 and IRS2, which serve as scaffolding adaptors linking the insulin and IGF1 receptors to PI3K-AKT activation. mTORC1 activation promotes IRS1 and IRS2 degradation through multiple serine phosphorylation events on these proteins mediated by mTORC1, S6K, or other unknown downstream protein kinases, thereby greatly dampening PI3K activation (Harrington et al., 2004; Shah and Hunter, 2006; Tzatsos and Kandror, 2006). Thus, mTORC1 inhibition increases IRS1 and



IRS2 stability and allows more robust and sustained insulin and IGF1 signaling to PI3K and AKT. Another adaptor protein, growth factor receptor bound protein 10 (GRB10), has also been found to be a direct target of mTORC1 that negatively regulates RTK signaling (Hsu et al., 2011; Yu et al., 2011). The mTORC1-mediated phosphorylation of GRB10 stabilizes the protein and enhances its ability to attenuate signaling from the insulin and IGF1 receptors and IRS proteins, thus blocking PI3K-AKT activation. There are also points of cross-talk between mTORC1 and mTORC2 that influence the full activation of AKT. S6K1-mediated phosphorylation of the mTORC2 components Rictor (T1135) and Sin1 (T86, T398) decreases the mTORC2-dependent phosphorylation of AKT-S473 (Dibble et al., 2009; Julien et al., 2010; Liu et al., 2013b). Curiously, this regulation of mTORC2 does not appear to affect its activity toward other substrates, including AKT T450. In addition to insulin and IGF1 signaling, mTOR inhibitors also enhance the activation of other RTKs upstream of PI3K and AKT. This includes members of the EGF Receptor family (EGFR, ErbB2 [also known as Her2], ErbB3 [also known as Her3], and ErbB4 [also known as [Her4]), which are acutely activated upon mTOR inhibition, without having immediate effects on receptor levels (Rodrik-Outmezguine et al., 2011). While the post-translational mechanisms underlying this regulation are not currently known, the effects are most prominently seen with mTOR kinase inhibitors, rather than the allosteric inhibitor rapamycin. As this class of compounds inhibits mTORC1 and mTORC2 equally, some of this feedback regulation could be mediated by mTORC2 signaling.

Other downstream branches of AKT signaling also exert feedback effects on AKT activation. In cancer research, the use of pharmacological compounds inhibiting PI3K isoforms, AKT, or mTOR have uncovered robust feedback regulation of RTK protein levels by the FoxO transcription factors (Chandarlapaty et al., 2011; Muranen et al., 2012; Zhuang et al., 2013). Prolonged inhibition of AKT signaling was found to enhance expression of the insulin and IGF1 receptors and HER3 through FoxO-dependent transcriptional induction, thereby rendering cells more prone to subsequent growth-factor-mediated activation of PI3K-AKT signaling (Chandarlapaty et al., 2011).


#### **Cross-Talk with Other Major Signaling Pathways**

Points of cross-regulation between the PI3K-AKT pathway and other major signaling pathways are common. These integration points act to either directly regulate pathway components or converge on the regulation of downstream targets controlled by other pathways. While it is plausible that PI3K-AKT signaling intersects with all major signal transduction pathways in cells at one or more points, the diversity and complexity of cross-talk mechanisms are exemplified by those with the RAS-ERK and AMPK pathways (Figure 6A).

There is a particularly intimate relationship between the PI3K-AKT and RAS-ERK pathways, where inhibitors of one pathway will often activate the other (Mendoza et al., 2011). One of the first substrates of AKT identified was the protein kinase c-Raf (or Raf1) (Rommel et al., 1999; Zimmermann and Moelling, 1999), which is activated by RAS and initiates a kinase cascade culminating in ERK activation. AKT phosphorylates c-RAF on S259 and an equivalent site on B-RAF (S364), which inhibits RAF activation or downstream signaling by promoting binding to 14-3-3

proteins, particularly when other regulatory sites on these proteins are also phosphorylated by PKA or AMPK (Dumaz and Marais, 2003; Guan et al., 2000; Shen et al., 2013; Zimmermann and Moelling, 1999). In addition to this point of direct cross-talk, many of the feedback mechanisms inherent to the AKT signaling network (discussed above) exert their effects through RTK signaling and scaffolding adaptors, which activate multiple mitogenic signaling pathways, including the RAS-ERK and PLC $\gamma$ -PKC pathways. ERK activation can also suppress RTK-mediated induction of the PI3K-AKT pathway via phosphorylation of the scaffolding adaptors GAB1 and GAB2 (Mendoza et al., 2011). An unbiased kinome-wide siRNA screen revealed that attenuation of ERK signaling results in a general enhancement of AKT activation, indicating that there are likely to be additional inhibitory mechanisms between these pathways (Lu et al., 2011). The PI3K-AKT and RAS-ERK pathways also converge to regulate many of the same downstream effectors (e.g., TSC2, FOXO, GSK3) and cellular processes (Mendoza et al., 2011). One clear example of this convergent regulation is in the control of cap-dependent translation. This occurs, in part, through mTORC1 regulation via ERK- and RSK-mediated multi-site phosphorylation of both TSC2 and the mTORC1 component Raptor (Ma et al., 2005; Romeo et al., 2012; Roux et al., 2004). Like RSK, the MAPK-interacting kinases (MNK1 and MNK2) are activated by ERK signaling. MNK1 and MNK2 phosphorylate the 5'-mRNA cap-binding protein eIF4E, which appears to promote its ability to initiate cap-dependent translation (Siddiqui and Sonenberg, 2015). This regulatory input from ERK signaling occurs downstream of the mTORC1-mediated phosphorylation of the 4E-BP proteins, which stimulates their release from inhibitory binding of eIF4E. Thus, while the PI3K-AKT and RAS-ERK pathways can cross-inhibit one another, they can also act in a cooperative manner to robustly regulate key cellular processes involved in cell growth and proliferation.

AKT signaling has several points of cross-regulation with AMPK, a master cellular energy sensor that facilitates adaptation to ATP depletion (Figure 6A). As AKT signaling promotes glucose uptake and glycolysis, it stimulates ATP production and thereby indirectly prevents AMPK activation; however, AKT has been found to directly phosphorylate a C-terminal residue on AMPK (AMPK $\alpha$ 1-S487), which hinders the activating phosphorylation of AMPK by LKB1 (Hawley et al., 2014; Horman et al., 2006). This regulation is interesting in light of the fact that AKT and AMPK have both redundant and counteracting functions in the regulation of cellular metabolism and growth. AMPK and AKT can both induce glucose uptake in metabolic tissues, such as skeletal muscle, through their respective phosphorylation and inhibition of the RAB-GAPs TBC1D1 and TBC1D4 (also known as AS160), resulting in RAB-mediated translocation of GLUT4 to the plasma membrane (Chavez et al., 2008; Eguez et al., 2005; Sano et al., 2003). While both kinases stimulate glucose uptake, they do so in response to distinct cues: AKT in response to insulin and AMPK in response to ATP depletion, such as what occurs during muscle contraction. On the other hand, AKT signaling, largely through its activation of mTORC1, stimulates ATP-consuming anabolic processes, whereas AMPK activation blocks anabolic metabolism in favor of ATP-producing catabolic processes (Dibble and Manning, 2013; Mihaylova and Shaw,



**Figure 6. Signaling Cross-Talk and Redundancy in the AKT Network**

(A) Several points of cross-regulation exist between the PI3K-AKT pathway and both the RAS-ERK and AMPK pathways, leading to both reciprocal pathway regulation and convergent regulation of downstream processes.

(B) Various AGC family kinases can redundantly phosphorylate overlapping sites on key downstream substrates of AKT, thereby altering the regulatory input into these targets.

kinases that are stimulated in a manner that is parallel to (e.g., SGK, RSK, PKC) or downstream of (e.g., S6K) AKT signaling. While alternative regulation through the same sequence motif might be the case for all AKT substrates, the three signaling nodes detailed above are excellent examples of this feature of the AKT signaling network (Figure 6B). The N-terminal inhibitory site on GSK3 isoforms (GSK3 $\alpha$ -S21, GSK3 $\beta$ -S9) can be phosphorylated by RSK or S6K, downstream of ERK or mTORC1 signaling, respectively (Kaidanovich-Beilin and Woodgett, 2011). The sequestration of FOXO3a in the cytosol can also be promoted by SGK-mediated phosphorylation of T32 (Brunet et al., 2001). Growth signals can activate mTORC1 signaling independent of AKT activity, including through the ERK-RSK pathway in a manner believed to involve RSK-mediated phosphorylation of at least two of the AKT sites on TSC2 (S939 and T1462), together with additional regulatory sites (Ma et al., 2005; Roux et al., 2004). Interestingly, SGK1 or SGK3 can also replace AKT for phosphorylation of TSC2 and induction of mTORC1 signaling, which was revealed in cancer cells upon prolonged exposure to pharmacological inhibitors of PI3K or AKT and provides a mechanism of cellular resistance to such inhibitors (Bago et al., 2016; Castel et al., 2016). In these examples, it appears that AKT is the dominant regulator, but this is unlikely to be the case for all AKT substrates and settings.

**Selective Signaling to Downstream Branches**

Given the diverse functions of AKT substrates, the ability to regulate subsets of downstream branches under different conditions would seem to be an essential feature; however, outside of differential expression of AKT substrates in a given biological context, this is a poorly understood area. A few parameters are likely to contribute to selective signaling to specific targets. The strength or duration of AKT activation might influence which substrates get phosphorylated. One indication of this property is in settings where mTORC2 is genetically or pharmacologically

2011). Through a variety of shared and distinct downstream targets, AKT and AMPK have opposing effects on mTORC1 signaling, protein, lipid, and glycogen synthesis and the induction of autophagy. Thus, cross-talk between these ubiquitous pathways is a key control point for adaptive switching between catabolic and anabolic states in cells and tissues.

**Modularity and Redundancy**

It is now well recognized that signaling is modular in nature and that substrates of AKT in one cell- and stimulus-specific context can be regulated by protein kinases related to AKT in another setting. This redundant regulation of substrates allows for key regulatory phosphorylation sites on a given protein to be responsive to a more diverse array of upstream inputs, which differentially regulate members of the AGC kinase family. This redundancy comes primarily through growth-factor-regulated

inhibited, thereby blocking AKT S473 phosphorylation, an event required to stabilize T308 phosphorylation for maximal AKT activation (Alessi et al., 1996a). Upon loss of mTORC2, unknown mechanisms are induced to stabilize T308 phosphorylation resulting in sustained AKT signaling (Guertin et al., 2006; Jacinto et al., 2006). The one notable exception is the AKT-mediated phosphorylation of FOXO isoforms, which is attenuated in the absence of mTORC2, despite the T308 compensation. One interpretation of these observations is that phosphorylation of FOXO, and perhaps other substrates, requires a higher threshold of AKT activity relative to other AKT substrates. Another likely mechanism directing differential substrate phosphorylation could be through spatial effects influencing AKT trafficking to its substrates or vice versa, which is an important future area of research.

For many AKT substrates, properties intrinsic to the substrate itself and its control by other regulatory inputs will direct specific downstream outputs. Through specific downstream targets, AKT signaling often intersects with cellular stress response and nutrient sensing pathways. In such cases, signals from intracellular stress or nutrient depletion are generally dominant over exogenous signals from growth factors and cytokines propagated by the PI3K-AKT pathway. For instance, opposing the AKT-mediated sequestration of FoxO family members in the cytosol (Figure 4B) are a number of stress- and nutrient-responsive pathways (e.g., p38, JNK, AMPK, SIRT1) that also directly modify FoxO transcription factors and promote their nuclear translocation and activation of gene targets, many of which are involved in adaptations to cellular stress (Webb and Brunet, 2014). TSC2 and mTORC1 are also subjected to opposing regulation that senses the depletion of intracellular ATP or nutrients and dominantly inhibits the ability of AKT signaling to activate mTORC1 (Saxton and Sabatini, 2017). Integration of these distinct signals assures that, regardless of the activation state of AKT, mTORC1 will not be activated to promote energy- and nutrient-consuming anabolic processes when these resources are limited. This manner of signal integration at the level of specific substrates, especially those that also play a role in feedback regulation of AKT, is likely key to matching the appropriate cellular response to the dynamically changing cellular state. For instance, growth factor signals to PI3K and AKT received in a cell that is nutrient deprived will result in enhanced survival signaling from AKT without the promotion of cell growth due to attenuation of mTORC1 signaling and its feedback effects on AKT. It seems likely that other such mechanisms exist that are inherent to specific AKT substrates that direct AKT action toward certain targets and away from others, thereby tailoring the signal to complement the cellular state.

### AKT Isoform-Specific Functions and Substrates

The majority of AKT substrates are phosphorylated and functionally regulated by all three AKT isoforms; however, a number of substrates have been identified that are uniquely targeted by AKT1, AKT2, or AKT3. This substrate selectivity likely accounts for some isoform-specific phenotypes observed in genetic studies, suggesting unique properties inherent to AKT isoforms or their regulation that account for such specificity. For example, independent breast cancer studies have shown that AKT1 sup-

presses migration and metastasis, whereas AKT2 promotes metastatic dissemination (Dillon et al., 2009; Hutchinson et al., 2004; Irie et al., 2005; Maroulakou et al., 2007); however, such opposing and non-redundant functions of AKT isoforms are likely to be context dependent. For example, in prostate cancer cells with *PTEN* inactivation, AKT2 is exclusively required for cell-autonomous tumor maintenance (Chin et al., 2014), whereas in *Pten*<sup>-/-</sup> mice, the AKT1 isoform appears to suppress prostate tumor development (Chen et al., 2006), while ablation of AKT2 has little impact (Xu et al., 2012). Global phospho-proteomic screening approaches have identified hundreds of novel phosphorylation sites that conform to the AKT consensus motif and have also provided new insights into potential AKT isoform-specific functions and substrates, many that await further validation (Lee et al., 2014; Moniz et al., 2017; Sanidas et al., 2014). Mechanisms that likely contribute to AKT isoform-specificity for downstream substrates include molecular features of individual isoforms, discrete subcellular localization, and relative expression levels in a given setting. Selective activation of specific AKT isoforms in certain settings might also contribute (Kim et al., 2011). Finally, the presence of oncogenic, activating somatic mutations in either AKT1, AKT2, or AKT3 will likely influence the pattern of specific substrate phosphorylation and signaling output (Lien et al., 2016). While the mechanistic aspects remain an interesting area of future investigation, clear evidence for AKT isoform-specific or -selective substrate phosphorylation has accumulated.

### Physiology and Pathology of AKT Signaling

Given the broad spectrum of AKT substrates and functions discovered through genetic, biochemical, and cell biological studies, it is not surprising that AKT plays a central but diverse role in the response of various cell types and tissues to hormones, growth factors, cytokines, and neurotrophic factors, among other stimuli. Mouse genetics indicate that AKT1, AKT2, and AKT3 have both redundant and specific functions in different tissues (Dummler and Hemmings, 2007). All tissues appear to express one or more AKT isoform, with AKT1 being the most widely expressed, AKT2 being enriched in insulin-responsive metabolic tissues, and AKT3 in the brain. Consistent with this tissue distribution, *Akt1*<sup>-/-</sup> mice display growth retardation and perinatal lethality (Chen et al., 2001; Cho et al., 2001b), *Akt2*<sup>-/-</sup> mice develop a diabetes-like syndrome (Cho et al., 2001a), *Akt3*<sup>-/-</sup> mice display decreased brain size (Easton et al., 2005; Tschopp et al., 2005), and compound knockouts develop a range of severe developmental abnormalities (Dummler and Hemmings, 2007). Here, we provide an overview of our current knowledge of AKT function in various organ systems and effects of AKT dysfunction in specific pathological states (Table 1).

### Overgrowth Syndromes

Multiple distinct overgrowth syndromes in humans have been associated with one or more genetic defects in the PI3K-AKT signaling network. The genetic lesions that are causally implicated in these syndromes all elicit a constitutive increase in AKT-TSC-mTORC1 signaling and include amplification or somatic mosaic mutations in *PIK3CA*, all three *AKT* isoforms, or *mTOR*, or germline inactivating mutations in *PTEN* or components of the TSC complex (Keppler-Noreuil et al., 2014). The

**Table 1. Physiological Functions of AKT and Pathological Implications from AKT Dysregulation in Different Cell Types and Tissues**

Cell type/tissue	Functions	Key targets	Potential disease implications*
Most cell types (epithelial or mesenchymal)	Survival and growth	Numerous targets	Overgrowth syndromes; adenoma; hamartoma; carcinoma; sarcoma
Endothelial cells and blood vessels	Survival and Angiogenesis	eNOS	Vascular anomalies; hemangioma; atherosclerosis.
Innate immune cells	Macrophage metabolism and polarization; Decreased inflammatory signals from dendritic cells; Neutrophil chemotaxis and respiratory burst	TSC-mTORC1, ACLY, FoxO1, GSK3	Chronic inflammatory diseases; sepsis
Lymphocytes	Thymocyte survival; Th cell activation; Treg suppression; CTL activation?; memory T cell suppression; B cell maturation, survival, and Ig class switching;	TSC-mTORC1, FoxO1	Autoimmune diseases
Neurons and CNS	Neuronal survival; polarity and axon specification; synaptic plasticity	TSC-mTORC1, GSK3, NFkB	Megalencephaly; epilepsy; autism; cognitive deficits; mood disorders; neurodegenerative diseases
Pancreas	Islet growth and insulin production	TSC-mTORC1	?
Liver	Suppress gluconeogenesis; lipid synthesis	FoxO, TSC-mTORC1	Insulin resistance, type 2 diabetes, hepatosteatosis
Adipose	Glucose uptake; suppression of lipolysis	TBC1D4, PDE3B, TSC-mTORC1, FoxO	Insulin resistance; type 2 diabetes; lipodystrophy
Muscle	Glucose uptake; glycogen synthesis; protein synthesis; suppression of protein degradation	TBC1D4, GSK3, TSC-mTORC1, FoxO	Insulin resistance; type 2 diabetes; sarcopenia
Hypothalamus	Suppress feeding	FoxO, TSC-mTORC1	Hyperphagia, obesity?
Heart	Physiological hypertrophy	TSC-mTORC1	Pathological hypertrophy?

\*Potential manifestations from aberrant activation or diminished Akt signaling in the given setting.

clinical manifestations of these overgrowth disorders range from small skin lesions to extreme overgrowth in multiple tissues and increased tumor susceptibility. For instance, PIK3CA-Related Overgrowth Spectrum (PROS) is a congenital or early childhood overgrowth syndrome, where patients are at risk for development of malignancies, consistent with activating *PIK3CA* hotspot mutations at E545K and H1047R being frequent events in sporadic carcinomas (Samuels et al., 2004). Proteus syndrome (PS) is a distinct progressive overgrowth abnormality in which affected individuals have a propensity to develop a range of benign tumors. The genetic basis for PS is a gain-of-function mutation in *AKT1* at E17K in the PH domain (Lindhurst et al., 2011). Affected individuals develop progressive overgrowth of most organs and tissues, in addition to severe vascular malformations. Patients with activating mutations in *AKT2* at E17K do not develop PS, but instead display severe insulin-independent hypoglycemia, asymmetric overgrowth, and obesity (Hussain et al., 2011). Patients with the equivalent *AKT3* E17K mutation develop brain overgrowth and megalencephaly (Poduri et al., 2012). The downstream TSC-mTORC1 branch appears to be particularly important in driving overgrowth in these syndromes associated with activation of the PI3K-AKT pathway, with patients often showing improvement upon treatment with mTORC1 inhibitors.

### Cancer

Multiple genetic lesions confer hyperactivation of AKT in human solid tumors and hematological malignancies. These include amplification or recurring oncogenic somatic mutations in *EGFR*, *HER2*, or other RTKs, *PDK1*, and *PIK3CA*. Similarly, inactivating mutations or loss-of-heterozygosity in tumor suppressor genes such as *PTEN*, *INPP4B*, and *PHLPP* also lead to hyperactivation of AKT (reviewed in Mayer and Arteaga [2016]); however, AKT activation is not always concordant with *PIK3CA* mutation (Vasudevan et al., 2009), and other PI3K effectors are also likely to contribute to malignancy (Lien et al., 2017). While AKT is most frequently activated in human cancers by mutations affecting upstream regulators, the three AKT isoforms themselves are bona fide oncogenes.

Albeit at lower frequencies than core AKT regulators, such as *PIK3CA*, amplification or activating mutations in the AKT genes have been identified in multiple solid tumors (Altomare and Testa, 2005). The first-described somatic activating mutation of any *Akt* gene was the E17K mutation in the PH domain of *AKT1* in breast cancer patients (Carpenter et al., 2007). *AKT1* E17K is a low-frequency (1.5%–9%) recurring mutation in breast cancers (Rudolph et al., 2016). This mutation confers constitutive kinase activation due to a charge switch at Glu17 in the phosphoinositide-binding pocket of the PH domain that allows

constitutive membrane localization of AKT (Carpten et al., 2007; Landgraf et al., 2008); however, AKT1 E17K is incapable of promoting tumorigenesis in the absence of other driver mutations (Lauring et al., 2010; Mancini et al., 2016). Like PIK3CA mutations, AKT E17K mutations are found in luminal, estrogen-receptor (ER)-positive breast cancers, suggesting that PI3K-AKT pathway activation confers a selective advantage in this lineage (Salhia et al., 2012). It is also noteworthy that, in addition to E17K, other activating mutations in AKT1 have been described in human cancers (Yi and Lauring, 2016). While the equivalent AKT2 E17K mutation has been identified in one breast cancer patient through a large-scale sequencing effort (Stephens et al., 2012), AKT2 E17K does not appear to be a recurring event in breast cancer. By contrast, the equivalent AKT3 E17K has been identified as a recurring mutation, particularly in melanoma (Davies et al., 2008). In all of these cases, the array of downstream pro-survival and pro-growth effects of AKT signaling, including changes to cellular metabolism, are likely to contribute to its role in tumor growth and progression (Manning and Cantley, 2007).

#### **Endothelial Cell Function, Angiogenesis, and Vascular Biology**

The AKT signaling network plays a major functional role in cells that are often dysregulated in vascular abnormalities, including endothelial cells (ECs), vascular smooth muscle cells (VSMCs), and macrophages. AKT1 appears to be the major isoform that contributes to normal EC physiological functions, and activation of AKT1 by vascular endothelial growth factor (VEGF) stimulates EC proliferation, migration, and survival (Chen et al., 2005). This is consistent with the finding that endothelial nitric oxide (NO) synthase (eNOS), which controls vascular tone, is an AKT1-specific substrate in endothelial cells (Lee et al., 2014). Thus, loss of AKT1, but not AKT2, in mouse ECs results in reduced NO release and impaired angiogenesis (Ackah et al., 2005). AKT1 has also been implicated in vascular remodeling. Expression of an activated AKT1 allele in ECs blocks the formation of neointimal lesions following arterial injury (Mukai et al., 2006) and induces pathological angiogenesis concomitant with increased vascular permeability (Phung et al., 2006).

AKT1 is the predominant isoform expressed in VSMCs and promotes VSMC cell proliferation, survival, and migration, with loss of AKT1 enhancing the development and severity of atherosclerosis in mouse models (Fernández-Hernando et al., 2007, 2009). Atherosclerosis is a widespread cardiovascular disorder that is dominated by the formation of localized vascular plaques comprised of lipid-laden macrophages, referred to as foam cells. AKT isoforms have prominent functions in macrophages related to innate immunity (see below), but they have also been found to influence foam cell formation. Mice lacking *Akt2*, but not *Akt1*, in hematopoietic cells display decreased atherosclerotic lesions (Babaev et al., 2014). By contrast, *Akt3* knockout mice have enhanced development of atherosclerosis due to an increase in formation of foam cells, which appears to be an intrinsic property of *Akt3*-deficient macrophages resulting from enhanced uptake of lipoproteins (Ding et al., 2012). Taken together with the critical functions of AKT1 in ECs and VSMCs, the three AKT isoforms play a complex, yet critical, role in vascular health and disease.

#### **Insulin Response and Systemic Metabolism**

In metazoans, AKT signaling has co-evolved with insulin and IGF1 signaling, with PI3K-dependent AKT activation being the primary effector pathway for these hormones in model organisms, including worms, flies, and rodents. In mammals, the insulin-mediated activation of AKT is central to proper glucose disposal and other metabolic adaptations after feeding through differential actions in metabolic tissues. Evidence suggests that AKT1 activation in pancreatic islet cells increases  $\beta$ -cell mass and insulin production (Buzzi et al., 2010). The TSC-Rheb-mTORC1 circuit is the likely downstream effector for this function, as islet cell-specific activation of mTORC1 results in a robust expansion of islets, hyperinsulinemia, and improved glucose tolerance (Howell and Manning, 2011). Post-prandial insulin secretion from the pancreas initiates the systemic metabolic response, which requires distinct functions of AKT in the major insulin-responsive tissues, including the liver, muscle, and fat. With some partial redundancy from AKT1, AKT2 appears to be the dominant functional isoform in these tissues for the response to insulin. As such, *Akt2* knockout mice exhibit insulin resistance and glucose intolerance and have type 2 diabetes (Cho et al., 2001a; Garofalo et al., 2003). Interestingly, rare dominant-negative mutations in *Akt2* have been found to underlie the genetic development of severe diabetes in humans (George et al., 2004). Importantly, AKT signaling is attenuated in metabolic tissues in the insulin-resistant state that underlies type 2 diabetes. Insulin resistance occurs, at least in part, through chronic activation of feedback and cross-talk mechanisms inherent to the PI3K-AKT signaling network (see above). The decreased ability to activate AKT disrupts the key metabolic actions of insulin.

Insulin signaling to AKT in the liver is essential for suppression of hepatic glucose production and for the stimulation of lipid synthesis (Dummler et al., 2006; Leavens et al., 2009; Ono et al., 2003). Insulin suppresses gluconeogenesis in hepatocytes via the AKT-mediated phosphorylation and inhibition of FoxO1, which in the fasted state resides in the nucleus and induces expression of the key gluconeogenic enzymes phosphoenolpyruvate carboxykinase (PEPCK) and glucose 6-phosphatase (G6Pase) (Matsumoto et al., 2007; Puigserver et al., 2003). Strikingly, the uncontrolled hepatic glucose production and insulin resistance in mice with liver-specific loss of *Akt1* and *Akt2* is reversed by co-deletion of *Foxo1* (Lu et al., 2012), providing definitive genetic evidence that inhibition of FoxO1 is an essential function of AKT in the liver. A particularly surprising implication of this finding is that in the absence of FoxO1, hepatic AKT signaling appears to be dispensable for the control of glucose metabolism by fasting and feeding. AKT signaling can also decrease hepatic glucose release by channeling glucose 6-phosphate toward glycogen synthesis; however, the insulin-stimulated, AKT2-dependent promotion of glycogen synthesis in the liver has been found to occur through an unknown mechanism that is independent of GSK3 phosphorylation (Wan et al., 2013). Insulin and AKT signaling in the liver also enhances de novo lipid synthesis, at least in part, through activation of the SREBP1c transcription factor (Leavens et al., 2009). Downstream of AKT, mTORC1 plays a major role in the activation of SREBP isoforms to promote de novo lipid synthesis (Düvel et al., 2010; Porstmann et al.,

2008). Induction of SREBP1c and lipid synthesis in the liver has been found to depend on both AKT2 and mTORC1, with FoxO1 suppression also contributing in this setting (Wang et al., 2015).

Another major effect of insulin on systemic metabolism is through the suppression of lipolysis and fatty acid release from adipose tissue, which likewise influences systemic insulin responsiveness (Czech et al., 2013). The inhibition of lipolysis is achieved, at least in part, through the suppression of catecholamine signaling to PKA, which induces lipolysis in the fasted state through the activation of acyl-glycerol lipases, including adipose triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL). PKA signaling promotes ATGL and HSL access to the triglyceride-rich lipid droplet of adipocytes, and insulin signaling attenuates this effect; however, an essential role for AKT in the ability of insulin to suppress lipolysis has not been fully established. Adipose-specific knockout of the mTORC2 component Rictor, which leads to attenuation of AKT signaling, results in a failure of insulin to block lipolysis (Kumar et al., 2010), but mice lacking AKT2 exhibit only a partial defect in insulin-mediated suppression of lipolysis (Koren et al., 2015). AKT has been found to directly phosphorylate phosphodiesterase 3B (PDE3B) on S273, which appears to enhance its ability to hydrolyze cAMP, thereby blocking PKA activation (Kitamura et al., 1999). Consistent with this being a key point of regulation, insulin fails to inhibit lipolysis in PDE3B knockout mice (Choi et al., 2006); however, the ability of insulin to block lipolysis is restored to PDE3B null adipocytes with re-expression of either wild-type PDE3B or a phosphorylation-site mutant (S273A), suggesting that other regulatory sites on PDE3B or parallel mechanism are also required for this regulation (DiPilato et al., 2015). Rapamycin-mediated inhibition of mTORC1, downstream of AKT, leads to an increase in plasma lipids in humans (Morrisett et al., 2002), and S6K1 knockout mice show a similar phenotype with a corresponding decrease in adiposity (Um et al., 2004). These effects have been attributed to a role for mTORC1 in suppressing lipolysis, as mTORC1 inhibition induces lipolysis in cultured adipocytes, which correlates with increased ATGL expression and PKA-dependent activating phosphorylation of HSL (Chakrabarti et al., 2010; Soliman et al., 2010). Recent studies have also found that the process of autophagy, which mTORC1 acutely inhibits, is intimately linked to the induction of lipolysis (Cingolani and Czaja, 2016).

The clearance of circulating glucose via uptake into adipose tissue and, especially, skeletal muscle is induced by insulin through the activation of AKT, predominantly AKT2 (Cho et al., 2001a; Garofalo et al., 2003). Insulin-stimulated PI3K-AKT signaling leads to rapid translocation of the primary glucose transporter in these tissues, GLUT4, to the plasma membrane (Leto and Saltiel, 2012). AKT2 has been found to associate with GLUT4-containing vesicles and promotes their trafficking and plasma membrane fusion in response to insulin (Calera et al., 1998; Ng et al., 2008). AKT appears to phosphorylate several direct downstream targets that regulate exocytosis of these vesicles (Leto and Saltiel, 2012). The best characterized of these is the Rab-GAP TBC1D4 (or AS160), which acts to retain Glut4-containing vesicles in the cytosol, a function that is disrupted by AKT-mediated phosphorylation of multiple regulatory

sites leading to TBC1D4 binding to 14-3-3 proteins (Eguez et al., 2005; Ramm et al., 2006; Sano et al., 2003). Subsequently, the newly acquired glucose from GLUT4-mediated uptake is stored as glycogen in skeletal muscle through the action of glycogen synthase, which is activated by AKT signaling via GSK3 phosphorylation and inhibition (McManus et al., 2005).

AKT signaling in response to insulin and IGF1 in skeletal muscle also enhances protein synthesis while attenuating protein breakdown (Egerman and Glass, 2014). Through its induction of protein synthesis and inhibition of autophagy, mTORC1 signaling is a major driver of IGF1-stimulated muscle hypertrophy (Ohanna et al., 2005; Rommel et al., 2001). Skeletal-muscle-specific knockout of mTORC1 results in muscle dystrophy (Bentzinger et al., 2008), and sustained mTORC1 signaling is sufficient to overcome atrophy during muscle immobilization (You et al., 2015); however, constitutive activation of mTORC1 in muscle can lead to organellar dysfunction and myopathy over time through chronic inhibition of autophagy (Castets et al., 2013). Interestingly, genetic activation of mTORC1 during denervation, which normally suppresses its activity, has been found to enhance muscle atrophy, at least in part through feedback suppression of AKT signaling to the FoxO transcription factors (Tang et al., 2014). AKT suppresses muscle protein breakdown through its inhibition of FoxO, thereby blocking expression of genes encoding the major muscle E3-ubiquitin ligases atrogin-1 and MuRF1 (Lee et al., 2004; Sandri et al., 2004; Stitt et al., 2004). By promoting an increase in muscle mass through such mechanisms, AKT signaling in skeletal muscle can improve systemic metabolism and overcome diet-induced obesity (Izumiya et al., 2008).

As a systemic negative feedback mechanism, insulin and leptin act on the hypothalamus to suppress food intake by stimulating AKT signaling to FoxO and mTORC1. Hypothalamic FoxO1 promotes food intake through the transcriptional induction of neuropeptide Y (NPY) and agouti-related peptide (AgRP), two major orexigenic peptides (Kim et al., 2006). AKT-mediated inhibition of FoxO1 in NPY- and AgRP-producing neurons blocks the synthesis of these peptides in response to insulin or leptin. The production of NPY and AgRP is also blocked by hypothalamic mTORC1-S6K1 signaling, thereby providing an additional suppressive signal on food intake (Blouet et al., 2008; Cota et al., 2006). Additional studies are needed to understand the role of AKT signaling in other regions of the brain that influence feeding behavior and the potential pathophysiological functions of AKT dysregulation in feeding disorders.

#### **Immunity and Autoimmune Diseases**

The PI3K-AKT pathway plays a diverse role in both myeloid cells of the innate immune system and lymphoid cells of the adaptive immune system. While the immunological functions of the AKT signaling network is a rather broad and active area of research, the focus here is on established cell-autonomous functions in these lineages.

A variety of different stimuli can activate AKT in myeloid cells, including specific growth factors, cytokines (e.g., IL-4), and ligands for toll-like receptors (TLRs; e.g., lipopolysaccharide [LPS]) and GPCRs (e.g., fMet-Leu-Phe [fMLP]). AKT activation stimulates a similar array of downstream effectors across the myeloid lineage, but how these signals impinge on the inflammatory action of each cell varies and is not well defined in most

cases. AKT has emerged as a mediator of macrophage polarization in response to different stimuli (Covarrubias et al., 2015; Weichhart et al., 2015). Polarization refers to specialized states adopted by activated macrophages (e.g., pro- or anti-inflammatory), which are dictated by the integration of diverse exogenous signals and alterations in the metabolic status of the cell. Along a continuum of functional states, the M1 state is the classical pro-inflammatory, anti-microbial macrophage promoted by LPS, whereas the M2 state mediates tissue repair, fibrosis, and response to parasitic infections and is induced by IL-4. While both M1 and M2 polarizing signals activate AKT, most genetic and pharmacological evidence suggests that AKT signaling promotes features of M2 macrophage polarization (Covarrubias et al., 2015; Weichhart et al., 2015); however, differential effects have been reported for AKT isoform-specific knockouts, with *Akt1* null macrophages polarized toward the M1 state and *Akt2* null macrophages toward M2 (Arranz et al., 2012; Babaev et al., 2014). What underlies this apparent functional difference is not well defined but suggests that AKT2 might oppose the action of AKT1 in its promotion of M2 polarization. The TSC-mTORC1 circuit appears to play an important role in the control of this process. Mouse genetic models suggest that mTORC1 activation opposes the M2-polarizing effects of PI3K-AKT signaling, with negative feedback mechanisms dominating this regulation (Byles et al., 2013; Jiang et al., 2014; Zhu et al., 2014). Consistent with mTORC1 functioning downstream of AKT in the promotion of M2 polarization, rapamycin has been found to selectively kill human M2 macrophages while enhancing M1 polarization (Mercalli et al., 2013). Alterations in cellular metabolism appear to underlie macrophage polarization (Covarrubias et al., 2015; Weichhart et al., 2015). Interestingly, AKT-induced glucose uptake, glycolysis, and production of cytosolic acetyl-CoA were recently found to promote M2 polarization by enhancing gene expression of specific targets in the M2 program, an effect largely attributed to epigenetic changes through directed histone acetylation (Covarrubias et al., 2016). An increase in ACLY-activating phosphorylation and protein levels downstream of AKT and mTORC1 were responsible for the increase in acetyl-CoA available for chromatin modifications. One mechanism by which AKT signaling might suppress M1 polarization in favor of M2 is through its inhibition of FoxO1, which promotes the expression of key M1 genes involved in inflammatory signaling, such as TLR4 (Fan et al., 2010). PI3K-AKT signaling in dendritic cells appears to dampen inflammatory signals, at least in part, by increasing expression of the anti-inflammatory cytokine IL-10 while decreasing expression of the pro-inflammatory cytokine IL-12 (Weichhart et al., 2015). Combined effects of the TSC-mTORC1, FoxO1, and GSK3 branches of AKT signaling likely contribute to this regulation. In addition, the mTORC1-inhibited process of autophagy has been suggested to play a key role in antigen processing and presentation by dendritic cells (Jagannath et al., 2009). In neutrophils, the control of cell polarity and chemotactic migration is key to their rapid response to infection or tissue damage. PI3K $\gamma$ , AKT2, and GSK3 are involved in the neutrophil response to GPCR agonists (e.g., fMLP), with mouse genetics demonstrating a prominent role in both neutrophil chemotaxis and induction of the respiratory burst involved in microbial killing (Chen et al., 2010b; Hirsch et al.,

2000; Li et al., 2000; Liu et al., 2010; Tang et al., 2011). As in macrophage lineages, opposing functions for AKT isoforms have been observed in neutrophils, with *Akt1*-deficient neutrophils displaying enhanced migration and bacterial killing (Liu et al., 2013a). These genetic studies suggest that AKT2 promotes the mobilization and activation of neutrophils, while AKT1 has suppressive effects.

PI3K signaling plays a diverse and critical role in T cell and B cell functions in the adaptive immune system (So and Fruman, 2012). In lymphocytes, it is predominantly the PI3K $\delta$  isoform that is activated by the T cell receptor (TCR), B cell receptor (BCR), and a variety of co-receptors and cytokine receptors, leading to activation of AKT and other effectors (Okkenhaug et al., 2002). The importance of properly linking transient PI3K-AKT activation to these coordinated immune signals is underscored by a variety of gain-of-function mouse models that give rise to severe lymphoproliferative and autoimmune disorders (Borlado et al., 2000; Parsons et al., 2001; Suzuki et al., 2001). AKT is important for the stimulated uptake of nutrients required for the survival and expansion of thymocyte populations, prior to differentiation into specific T cell lineages (Juntilla et al., 2007). Different classes of CD4<sup>+</sup> T-helper (Th) cells exist that are defined by the cytokines they produce, which differentially influence the activity of other cells of both the innate and adaptive immune systems. The differentiation and clonal expansion of these populations involves AKT signaling to the TSC-mTORC1 circuit and FOXO family members, which serve to promote Th1, Th2, and Th17 cell differentiation while hindering the development of immunosuppressive Tregs (Delgoffe et al., 2009, 2011; Gerriets et al., 2016; Kerdiles et al., 2010; Ouyang et al., 2010). While antigen and cytokine stimulation of CD8<sup>+</sup> T cells activate the PI3K-AKT pathway, the functional consequence of this signal is not entirely clear (Macintyre et al., 2011); however, mTORC1 plays an essential role in the differentiation and expansion of CD8<sup>+</sup> cytotoxic T lymphocytes (CTLs) while attenuating the development of memory CD8<sup>+</sup> T cells (Pollizzi et al., 2015). As in other cell types (Düvel et al., 2010), mTORC1 activation promotes glucose uptake, glycolysis, and lipid synthesis to drive differentiation and anabolic cell proliferation in both Th cells and CTLs, while these metabolic changes appear to suppress Treg and memory cell functions (Gerriets et al., 2016; Kidani et al., 2013; Pollizzi et al., 2015; Shi et al., 2011). In B cell development, PI3K-AKT signaling is required for transition of pro-B cells into IgM-expressing immature B cells (Okkenhaug et al., 2002). This process requires suppression of the recombination-activating gene (RAG) loci *Rag1* and *Rag2*, which is mediated through AKT-dependent inhibition of FoxO1, a transcriptional activator of these genes (Amin and Schlissel, 2008). AKT signaling to FoxO1 also plays key roles in the maturation and survival of peripheral B cell populations and Ig class switching (Calamito et al., 2010; Chen et al., 2010a; Omori et al., 2006).

The opposing cell intrinsic functions of different AKT isoforms in distinct myeloid and lymphoid lineages, together with the critical communication between these populations of innate and adaptive immune cells that varies with the given challenge, makes interpretation of studies using whole body knockouts of AKT isoforms or systemic administration of PI3K, AKT, or mTOR inhibitors challenging at a mechanistic level.

### Neuronal Functions and Neurological Disorders

AKT signaling plays important roles in neuronal survival, growth, polarity, synaptic plasticity, and circuitry, thereby influencing brain development and function with implications in a diverse set of neurological disorders. In the developing brain, PI3K-AKT signaling is activated by a variety of growth and neurotrophic factors (e.g., IGF1, nerve-growth factor [NGF], brain-derived neurotrophic factor [BDNF]) and controls neuronal survival and morphology. The AKT-mediated inhibition of the proapoptotic protein Bad and Foxo transcription factors promotes neuronal cell survival (Brunet et al., 1999; Datta et al., 2000). Localized PI3K-AKT pathway activation and its inhibitory phosphorylation of GSK3 drives axon specification in neurites of developing neurons by activating collapsin response mediator protein 2 (CRMP-2), which associates with axonal growth cones in a manner that is inhibited by GSK3 (Jiang et al., 2005; Yoshimura et al., 2005). Through its activation of mTORC1, AKT signaling promotes the growth of multiple populations of brain cells, including neurons and astroglial cells, and plays a critical role in both developmental brain growth and pathological growth underlying megalencephaly and cortical malformations (Lipton and Sahin, 2014). The dynamic process of synapse formation (i.e., synaptic plasticity) is tightly regulated and required for the establishment of proper neuronal circuits and memory. Activation of AKT and mTORC1 signaling is important in the control of synaptic plasticity, affecting both long-term potentiation (LTP) and long-term depression (LTD) through its induction of localized protein synthesis (Hou and Klann, 2004; Li et al., 2010; Tang et al., 2002).

Dysregulation of the AKT signaling network underlies numerous neurodevelopmental, neurocognitive, neuropsychiatric, and neurodegenerative disorders. Germline or somatic mosaic mutations leading to increased activation of PI3K-AKT-mTORC1 signaling are frequently associated with epilepsy, autism spectrum disorders, and intellectual disabilities, a point that is exemplified by the multi-faceted TSC disease (Lipton and Sahin, 2014). Decreased AKT signaling has been associated with a number of mood disorders, including depression, schizophrenia, and bipolar disorder. Depression is believed to be caused by localized synaptic deficits and is associated with decreases in BDNF signaling to AKT and mTORC1, which can be reversed by anti-depressant drugs such as ketamine (Abdallah et al., 2015). Increased GSK3 activity upon attenuation of AKT signaling also contributes to depression, as well as schizophrenia and bipolar disorder (Emamian et al., 2004; Kaidanovich-Beilin and Woodgett, 2011). *Gsk3 $\alpha$ <sup>-/-</sup>* or *Gsk3 $\beta$ <sup>+/-</sup>* mice display anti-depression-like behaviors that mimic those of animals on lithium, a GSK3 selective inhibitor used to treat mood disorders. While *Gsk3 $\alpha$ <sup>S21A</sup>*; *Gsk3 $\beta$ <sup>S9A</sup>* mice are developmentally normal (McManus et al., 2005), they are sensitive to hyperactivity with phenotypes associated with anxiety in response to environmental changes and stress (Kaidanovich-Beilin and Woodgett, 2011; Polter et al., 2010). Various studies have also linked dysfunctional signaling of AKT and its downstream targets to neurodegenerative diseases, including Alzheimer's. In the brains of Alzheimer's patients, AKT signaling to GSK3 and mTORC1 appears elevated (An et al., 2003; Griffin et al., 2005). It has been suggested that mTORC1-mediated inhibition of autophagy

might hinder the clearance of pathological protein aggregates in Alzheimer's and other neurodegenerative diseases (Nixon, 2013). GSK3 has been implicated in Alzheimer's disease and directly phosphorylates several proteins that contribute to the pathology of the disease, including amyloid precursor protein, presenilin, and tau (Kaidanovich-Beilin and Woodgett, 2011) (Figure 3); however, it is not clear whether this function of GSK3 is influenced by AKT signaling. Additional studies are needed to understand the role of FOXO family members in neurodegeneration, as there is increasing evidence that FOXO can promote the clearance of misfolded proteins (Webb and Brunet, 2014).

### Therapeutic Targeting of AKT

While it is clear that PI3K-AKT signaling influences a wide variety of human diseases, therapeutic development of AKT inhibitors has been largely restricted to oncology. Over 50% of human tumors display hyperactivation of AKT. Over the last decade, numerous specific and potent PI3K pathway small molecule inhibitors have entered clinical trials. The *in vitro* use of two PI3K inhibitors, LY294002 and wortmannin, was instrumental in decoding many of the mechanisms by which PI3K initiates signaling, including AKT activation; however, subsequent studies showed that both compounds, in addition to blocking all PI3K isoforms, also directly inhibit mTOR, which is a PI3K-related protein kinase (Brunn et al., 1996). As more specific and potent PI3K and AKT inhibitors have since been developed, it is highly recommended that wortmannin and LY294002 no longer be used to make specific conclusions regarding the functions of PI3K or AKT. Some efficacy and therapeutic benefits have been observed in patients treated with new classes of PI3K inhibitors, but their use can be limited by significant toxicity (Mayer and Arteaga, 2016). Several AKT small molecule inhibitors have also been developed and are currently undergoing clinical evaluation.

A large number of ATP-competitive AKT inhibitors have been developed. Given the high degree of similarity of the ATP-binding pocket among AGC family kinases, it is not surprising that a lack of specificity is a major caveat of active site inhibitors. GSK690693 inhibits all AKT isoforms and showed efficacy in a number of preclinical studies, but dose-limiting toxicities that are likely on target, associated with hyperglycemia, led to termination of the clinical development of this drug (Crouthamel et al., 2009; Rhodes et al., 2008). AZD5363 is a nanomolar pan-AKT inhibitor that has shown efficacy in a number of hematological cancers and solid tumor models (Crabb et al., 2017; Davies et al., 2012). One of the more clinically advanced catalytic inhibitors is GDC0068 (Ipatasertib), a highly potent and specific orally bioavailable inhibitor of all three AKT isoforms. Although GDC0068 has shown efficacy in preclinical models with PTEN inactivation or PIK3CA mutation (Lin et al., 2013), a phase I trial did not reveal significant antitumor activity (Saura et al., 2017). Afuresertib or GSK2110183, which inhibits AKT1 in the subnanomolar and AKT2 and AKT3 in the low nanomolar range, has also shown potent activity in preclinical models and, in phase I trials, appears to be well-tolerated (Dumble et al., 2014).

Catalytic AKT inhibitors block the phosphorylation of downstream substrates in a dose-dependent manner, but actually protect AKT from dephosphorylation at T308 and S473 (Lin



et al., 2012; Okuzumi et al., 2009). Moreover, catalytic AKT inhibitors actually enhance PI3,4P<sub>2</sub> and PIP<sub>3</sub> binding, since the kinase adopts a conformation where the PH domain is released from its inhibitory interactions with the catalytic domain, leading to enhanced membrane binding (Vivanco et al., 2014). In a direct comparison, catalytic inhibitors show less efficacy in promoting cell death than allosteric inhibitors that target the PH domain (Vivanco et al., 2014) (see below).

MK2206 is a specific, potent, and orally bioavailable allosteric AKT inhibitor that targets both the PH and catalytic domains (Hirai et al., 2010) and induces robust cancer cell death both alone and in combination with other compounds (Wisinski et al., 2016). As single agent therapy, however, MK2206 has not shown significant efficacy in the clinic (Ma et al., 2016). Unlike catalytic inhibitors, allosteric inhibitors target the closed, inactive conformation of AKT where the PH domain engages the kinase domain, thereby preventing phosphorylation and activation (Barnett et al., 2005; Hirai et al., 2010). Consistent with the notion that the AKT E17K mutation is constitutively membrane bound, this oncogenic AKT allele is less sensitive to MK2206 (Parikh et al., 2012). Finally, ARQ092 is a structurally distinct allosteric inhibitor that targets all three AKT isoforms, potently inhibits AKT signaling, and is currently under evaluation in phase I trials (Lapierre et al., 2016; Yu et al., 2015).

To date, both catalytic and allosteric inhibitors have shown limited efficacy in the clinic. A possible contributing factor to the lack of significant antitumor responses observed with all AKT inhibitors is a lack of patient stratification for those with activating AKT or PIK3CA mutations in the corresponding trials. In trials where patients were selected for the presence of pathway mutations—for example, the AKT1 E17K mutation—a number of patients showed partial responses when treated with AZD5363 (Davies et al., 2012). Moreover, the relief of feedback inhibition in tumors treated with AKT inhibitors leads to a rebound effect, resulting in robust PI3K pathway activation, thereby limiting the efficacy of such inhibitors, at least as single agents (Chandarlapaty et al., 2011). Importantly, PI3K pathway mutations, such as oncogenic PIK3CA, do not always coincide with elevated phosphorylation of AKT, with other PI3K effectors such as SGK isoforms driving downstream signaling in some settings (Vasudevan et al., 2009). The emergence of resistance to AKT inhibitors poses a major challenge to the effective implementation of small molecule inhibitors targeting the PI3K-AKT network in patients. These resistance mechanisms include increased expression of SGK isoforms (Bago et al., 2016; Sommer et al., 2013), further illustrating the challenge of overcoming regulatory redundancy within the network (see above).

Despite the specific functions and substrates attributed to the three AKT isoforms in pathobiology, highly selective and potent AKT isoform-specific inhibitors have yet to be developed. Based on our knowledge of isoform-specific AKT functions, optimizing AKT inhibitors to spare AKT2 might be particularly effective at relieving the major on-target toxicity of hyperglycemia in cancer settings, where AKT1 or AKT3 are the primary drivers.

### Conclusions and Perspectives

The past 25 years of research on the AKT protein kinases has revealed an intricate molecular blueprint of AKT regulation and

function and increasing insights into its role in cell, tissue, and organismal physiology. The diverse functional repertoire of AKT stems from the numerous downstream substrates that have evolved regulatory sequences that link the control of their cellular function to the myriad of upstream signals that stimulate AKT activity. The ever-expanding list of AKT substrates and their overlap and cross-talk with other major cellular signaling networks creates a dynamic environment, where the integration of distinct signals at the level of multiple downstream effectors is required for a cell to mount an appropriate response. It is now well recognized that signals from a combination of exogenous ligands and nutrients are perceived in a context of parallel cues monitored by pathways that sense intracellular nutrients, energy, and various stresses. Layered on top of this are feedback mechanisms, threshold effects, and spatial and temporal influences on signal propagation. Thus, the days of thinking about signal transduction in a binary, on-off fashion are long past. While the one-signal, one-substrate, one-function paradigm remains useful for reductionist research and will continue to play an essential role in discovering new components of signaling networks, we must also recognize and embrace the network-based view. The reality of the complexity of integrated signaling networks dictates that all signaling is contextual by nature, a fact that often leads to misinterpretation or overinterpretation of data. Now that the complexity of AKT signaling is glaringly evident, unraveling the detailed circuitry of the network and the strategies it employs to propagate cellular information will require novel biochemical, cell biological, genetic, computational, and systems approaches. Only with a more sophisticated understanding of the wiring and dynamic rewiring of the PI3K-AKT signaling network will we really grasp how to pharmacologically or biologically manipulate the network to treat the diverse set of human diseases exhibiting pathological features elicited by its dysregulation.

### AUTHOR CONTRIBUTIONS

B.D.M. and A.T. conceptualized, researched, and wrote this review.

### ACKNOWLEDGMENTS

We apologize to the many colleagues and contributors over the last 25 years of research in the field whose work has added to our understanding of the AKT network but could not be cited due to space limitations. This work was supported by grants from the National Institutes of Health (R35-CA197459 and P01-CA120964 to B.D.M.; R01-CA200671 and R01-CA177910 to A.T.) and from the Ludwig Center at Harvard (A.T.)

### REFERENCES

- Abdallah, C.G., Sanacora, G., Duman, R.S., and Krystal, J.H. (2015). Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. *Annu. Rev. Med.* 66, 509–523.
- Ackah, E., Yu, J., Zoellner, S., Iwakiri, Y., Skurk, C., Shibata, R., Ouchi, N., Easton, R.M., Galasso, G., Birnbaum, M.J., et al. (2005). Akt1/protein kinase B $\alpha$  is critical for ischemic and VEGF-mediated angiogenesis. *J. Clin. Invest.* 115, 2119–2127.
- Alessi, D.R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P., and Hemmings, B.A. (1996a). Mechanism of activation of protein kinase B by insulin and IGF-1. *EMBO J.* 15, 6541–6551.

- Alessi, D.R., Caudwell, F.B., Andjelkovic, M., Hemmings, B.A., and Cohen, P. (1996b). Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. *FEBS Lett.* 399, 333–338.
- Alessi, D.R., James, S.R., Downes, C.P., Holmes, A.B., Gaffney, P.R., Reese, C.B., and Cohen, P. (1997). Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B. *Curr. Biol.* 7, 261–269.
- Altomare, D.A., and Testa, J.R. (2005). Perturbations of the AKT signaling pathway in human cancer. *Oncogene* 24, 7455–7464.
- Amin, R.H., and Schlissel, M.S. (2008). Foxo1 directly regulates the transcription of recombination-activating genes during B cell development. *Nat. Immunol.* 9, 613–622.
- An, W.L., Cowburn, R.F., Li, L., Braak, H., Alafuzoff, I., Iqbal, K., Iqbal, I.G., Winblad, B., and Pei, J.J. (2003). Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. *Am. J. Pathol.* 163, 591–607.
- Andjelković, M., Jakubowicz, T., Cron, P., Ming, X.F., Han, J.W., and Hemmings, B.A. (1996). Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. *Proc. Natl. Acad. Sci. USA* 93, 5699–5704.
- Arranz, A., Doxaki, C., Vergadi, E., Martinez de la Torre, Y., Vaporidi, K., Lagoudaki, E.D., Ieronymaki, E., Androulidaki, A., Venihaki, M., Margioris, A.N., et al. (2012). Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization. *Proc. Natl. Acad. Sci. USA* 109, 9517–9522.
- Auger, K.R., Serunian, L.A., Soltoff, S.P., Libby, P., and Cantley, L.C. (1989). PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells. *Cell* 57, 167–175.
- Babaev, V.R., Hebron, K.E., Wiese, C.B., Toth, C.L., Ding, L., Zhang, Y., May, J.M., Fazio, S., Vickers, K.C., and Linton, M.F. (2014). Macrophage deficiency of Akt2 reduces atherosclerosis in Ldlr null mice. *J. Lipid Res.* 55, 2296–2308.
- Bago, R., Sommer, E., Castel, P., Crafter, C., Bailey, F.P., Shpiro, N., Baselga, J., Cross, D., Evers, P.A., and Alessi, D.R. (2016). The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth. *EMBO J.* 35, 2263.
- Barnett, S.F., Defeo-Jones, D., Fu, S., Hancock, P.J., Haskell, K.M., Jones, R.E., Kahana, J.A., Kral, A.M., Leander, K., Lee, L.L., et al. (2005). Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. *Biochem. J.* 385, 399–408.
- Bellacosa, A., Testa, J.R., Staal, S.P., and Tschlis, P.N. (1991). A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. *Science* 254, 274–277.
- Bentzinger, C.F., Romanino, K., Cloëtta, D., Lin, S., Mascarenhas, J.B., Oliveri, F., Xia, J., Casanova, E., Costa, C.F., Brink, M., et al. (2008). Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. *Cell Metab.* 8, 411–424.
- Berwick, D.C., Hers, I., Heesom, K.J., Moule, S.K., and Tavare, J.M. (2002). The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes. *J. Biol. Chem.* 277, 33895–33900.
- Blouet, C., Ono, H., and Schwartz, G.J. (2008). Mediobasal hypothalamic p70 S6 kinase 1 modulates the control of energy homeostasis. *Cell Metab.* 8, 459–467.
- Borlado, L.R., Redondo, C., Alvarez, B., Jimenez, C., Criado, L.M., Flores, J., Marcos, M.A., Martinez-A, C., Balomenos, D., and Carrera, A.C. (2000). Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. *FASEB J.* 14, 895–903.
- Bozulich, L., Surucu, B., Hynx, D., and Hemmings, B.A. (2008). PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. *Mol. Cell* 30, 203–213.
- Braccini, L., Ciraolo, E., Campa, C.C., Perino, A., Longo, D.L., Tibolla, G., Pregnolato, M., Cao, Y., Tassone, B., Damilano, F., et al. (2015). PI3K-C2γ is a Rab5 effector selectively controlling endosomal Akt2 activation downstream of insulin signalling. *Nat. Commun.* 6, 7400.
- Brogna, J., Sierecki, E., Gao, T., and Newton, A.C. (2007). PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. *Mol. Cell* 25, 917–931.
- Brunet, A., Bonni, A., Zigmond, M.J., Lin, M.Z., Juo, P., Hu, L.S., Anderson, M.J., Arden, K.C., Blenis, J., and Greenberg, M.E. (1999). Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. *Cell* 96, 857–868.
- Brunet, A., Park, J., Tran, H., Hu, L.S., Hemmings, B.A., and Greenberg, M.E. (2001). Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). *Mol. Cell Biol.* 21, 952–965.
- Brunn, G.J., Williams, J., Sabers, C., Wiederrecht, G., Lawrence, J.C., Jr., and Abraham, R.T. (1996). Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. *EMBO J.* 15, 5256–5267.
- Burgering, B.M., and Coffey, P.J. (1995). Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. *Nature* 376, 599–602.
- Buzzi, F., Xu, L., Zuellig, R.A., Boller, S.B., Spinass, G.A., Hynx, D., Chang, Z., Yang, Z., Hemmings, B.A., Tschopp, O., and Niessen, M. (2010). Differential effects of protein kinase B/Akt isoforms on glucose homeostasis and islet mass. *Mol. Cell Biol.* 30, 601–612.
- Byles, V., Covarrubias, A.J., Ben-Sahra, I., Lamming, D.W., Sabatini, D.M., Manning, B.D., and Horng, T. (2013). The TSC-mTOR pathway regulates macrophage polarization. *Nat. Commun.* 4, 2834.
- Calamito, M., Juntilla, M.M., Thomas, M., Northrup, D.L., Rathmell, J., Birnbaum, M.J., Koretzky, G., and Allman, D. (2010). Akt1 and Akt2 promote peripheral B-cell maturation and survival. *Blood* 115, 4043–4050.
- Calera, M.R., Martinez, C., Liu, H., Jack, A.K., Birnbaum, M.J., and Pilch, P.F. (1998). Insulin increases the association of Akt-2 with Glut4-containing vesicles. *J. Biol. Chem.* 273, 7201–7204.
- Calleja, V., Alcor, D., Laguerre, M., Park, J., Vojnovic, B., Hemmings, B.A., Downward, J., Parker, P.J., and Larjani, B. (2007). Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo. *PLoS Biol.* 5, e95.
- Calleja, V., Laguerre, M., Parker, P.J., and Larjani, B. (2009). Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition. *PLoS Biol.* 7, e17.
- Cantley, L.C. (2004–2005). The role of phosphoinositide 3-kinase in human disease. *Harvey Lect.* 100, 103–122.
- Carpten, J.D., Faber, A.L., Horn, C., Donoho, G.P., Briggs, S.L., Robbins, C.M., Hostetter, G., Boguslawski, S., Moses, T.Y., Savage, S., et al. (2007). A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. *Nature* 448, 439–444.
- Castel, P., Ellis, H., Bago, R., Toska, E., Razavi, P., Carmona, F.J., Kannan, S., Verma, C.S., Dickler, M., Chandarlapaty, S., et al. (2016). PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition. *Cancer Cell* 30, 229–242.
- Castets, P., Lin, S., Rion, N., Di Fulvio, S., Romanino, K., Guridi, M., Frank, S., Tintignac, L.A., Sinnreich, M., and Rüegg, M.A. (2013). Sustained activation of mTORC1 in skeletal muscle inhibits constitutive and starvation-induced autophagy and causes a severe, late-onset myopathy. *Cell Metab.* 17, 731–744.
- Chakrabarti, P., English, T., Shi, J., Smas, C.M., and Kandror, K.V. (2010). Mammalian target of rapamycin complex 1 suppresses lipolysis, stimulates lipogenesis, and promotes fat storage. *Diabetes* 59, 775–781.
- Chan, C.H., Li, C.F., Yang, W.L., Gao, Y., Lee, S.W., Feng, Z., Huang, H.Y., Tsai, K.K., Flores, L.G., Shao, Y., et al. (2012). The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. *Cell* 149, 1098–1111.
- Chan, C.H., Jo, U., Kohrman, A., Rezaeian, A.H., Chou, P.C., Logothetis, C., and Lin, H.K. (2014). Posttranslational regulation of Akt in human cancer. *Cell Biosci.* 4, 59.
- Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P.K., Baselga, J., and Rosen, N. (2011).

- AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. *Cancer Cell* 19, 58–71.
- Chavez, J.A., Roach, W.G., Keller, S.R., Lane, W.S., and Lienhard, G.E. (2008). Inhibition of GLUT4 translocation by Tbc1d1, a Rab GTPase-activating protein abundant in skeletal muscle, is partially relieved by AMP-activated protein kinase activation. *J. Biol. Chem.* 283, 9187–9195.
- Chen, W.S., Xu, P.Z., Gottlob, K., Chen, M.L., Sokol, K., Shiyanova, T., Roninson, I., Weng, W., Suzuki, R., Tobe, K., et al. (2001). Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. *Genes Dev.* 15, 2203–2208.
- Chen, J., Somanath, P.R., Razorenova, O., Chen, W.S., Hay, N., Bornstein, P., and Byzova, T.V. (2005). Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. *Nat. Med.* 11, 1188–1196.
- Chen, M.L., Xu, P.Z., Peng, X.D., Chen, W.S., Guzman, G., Yang, X., Di Cristofano, A., Pandolfi, P.P., and Hay, N. (2006). The deficiency of Akt1 is sufficient to suppress tumor development in Pten<sup>+/-</sup> mice. *Genes Dev.* 20, 1569–1574.
- Chen, J., Limon, J.J., Blanc, C., Peng, S.L., and Fruman, D.A. (2010a). Foxo1 regulates marginal zone B-cell development. *Eur. J. Immunol.* 40, 1890–1896.
- Chen, J., Tang, H., Hay, N., Xu, J., and Ye, R.D. (2010b). Akt isoforms differentially regulate neutrophil functions. *Blood* 115, 4237–4246.
- Chen, M., Pratt, C.P., Zeeman, M.E., Schultz, N., Taylor, B.S., O'Neill, A., Castillo-Martin, M., Nowak, D.G., Naguib, A., Grace, D.M., et al. (2011). Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. *Cancer Cell* 20, 173–186.
- Chiang, G.G., and Abraham, R.T. (2005). Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. *J. Biol. Chem.* 280, 25485–25490.
- Chin, Y.R., Yuan, X., Balk, S.P., and Toker, A. (2014). PTEN-deficient tumors depend on AKT2 for maintenance and survival. *Cancer Discov.* 4, 942–955.
- Cho, H., Mu, J., Kim, J.K., Thorvaldsen, J.L., Chu, Q., Crenshaw, E.B., 3rd, Kaestner, K.H., Bartolomei, M.S., Shulman, G.I., and Birnbaum, M.J. (2001a). Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). *Science* 292, 1728–1731.
- Cho, H., Thorvaldsen, J.L., Chu, Q., Feng, F., and Birnbaum, M.J. (2001b). Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. *J. Biol. Chem.* 276, 38349–38352.
- Choi, Y.H., Park, S., Hockman, S., Zmuda-Trzebiatowska, E., Svnenelid, F., Haluzik, M., Gavriloova, O., Ahmad, F., Pepin, L., Napolitano, M., et al. (2006). Alterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3B-null mice. *J. Clin. Invest.* 116, 3240–3251.
- Cingolani, F., and Czaja, M.J. (2016). Regulation and Functions of Autophagic Lipolysis. *Trends Endocrinol. Metab.* 27, 696–705.
- Coffer, P.J., and Woodgett, J.R. (1991). Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. *Eur. J. Biochem.* 201, 475–481.
- Collins, B.J., Deak, M., Arthur, J.S., Armit, L.J., and Alessi, D.R. (2003). In vivo role of the PIF-binding docking site of PDK1 defined by knock-in mutation. *EMBO J.* 22, 4202–4211.
- Cota, D., Proulx, K., Smith, K.A., Kozma, S.C., Thomas, G., Woods, S.C., and Seeley, R.J. (2006). Hypothalamic mTOR signaling regulates food intake. *Science* 312, 927–930.
- Covarrubias, A.J., Aksoylar, H.I., and Horng, T. (2015). Control of macrophage metabolism and activation by mTOR and Akt signaling. *Semin. Immunol.* 27, 286–296.
- Covarrubias, A.J., Aksoylar, H.I., Yu, J., Snyder, N.W., Worth, A.J., Iyer, S.S., Wang, J., Ben-Sahra, I., Byles, V., Polynne-Stapornkul, T., et al. (2016). Akt-mTORC1 signaling regulates Acly to integrate metabolic input to control of macrophage activation. *eLife* 5, e11612.
- Crabb, S.J., Birtle, A.J., Martin, K., Downs, N., Ratcliffe, I., Maishman, T., Ellis, M., Griffiths, G., Thompson, S., Ksiazek, L., et al. (2017). ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer. *Invest. New Drugs.* Published online February 1, 2017. <http://dx.doi.org/10.1007/s10637-017-0433-4>.
- Cross, D.A., Alessi, D.R., Cohen, P., Andjelkovich, M., and Hemmings, B.A. (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. *Nature* 378, 785–789.
- Crouthamel, M.C., Kahana, J.A., Korenchuk, S., Zhang, S.Y., Sundaresan, G., Eberwein, D.J., Brown, K.K., and Kumar, R. (2009). Mechanism and management of AKT inhibitor-induced hyperglycemia. *Clin. Cancer Res.* 15, 217–225.
- Czech, M.P., Tencerova, M., Pedersen, D.J., and Aouadi, M. (2013). Insulin signalling mechanisms for triacylglycerol storage. *Diabetologia* 56, 949–964.
- Dajani, R., Fraser, E., Roe, S.M., Young, N., Good, V., Dale, T.C., and Pearl, L.H. (2001). Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. *Cell* 105, 721–732.
- Datta, S.R., Katsov, A., Hu, L., Petros, A., Fesik, S.W., Yaffe, M.B., and Greenberg, M.E. (2000). 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. *Mol. Cell* 6, 41–51.
- Davies, M.A., Stenke-Hale, K., Tellez, C., Calderone, T.L., Deng, W., Prieto, V.G., Lazar, A.J., Gershenwald, J.E., and Mills, G.B. (2008). A novel AKT3 mutation in melanoma tumours and cell lines. *Br. J. Cancer* 99, 1265–1268.
- Davies, B.R., Greenwood, H., Dudley, P., Crafter, C., Yu, D.H., Zhang, J., Li, J., Gao, B., Ji, Q., Maynard, J., et al. (2012). Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. *Mol. Cancer Ther.* 11, 873–887.
- Delgoffe, G.M., Kole, T.P., Zheng, Y., Zarek, P.E., Matthews, K.L., Xiao, B., Worley, P.F., Kozma, S.C., and Powell, J.D. (2009). The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. *Immunity* 30, 832–844.
- Delgoffe, G.M., Pollizzi, K.N., Waickman, A.T., Heikamp, E., Meyers, D.J., Horton, M.R., Xiao, B., Worley, P.F., and Powell, J.D. (2011). The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. *Nat. Immunol.* 12, 295–303.
- Di Maira, G., Salvi, M., Arrighi, G., Marin, O., Sarno, S., Brustolon, F., Pinna, L.A., and Ruzzene, M. (2005). Protein kinase CK2 phosphorylates and upregulates Akt/PKB. *Cell Death Differ.* 12, 668–677.
- Dibble, C.C., and Manning, B.D. (2013). Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. *Nat. Cell Biol.* 15, 555–564.
- Dibble, C.C., Asara, J.M., and Manning, B.D. (2009). Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. *Mol. Cell Biol.* 29, 5657–5670.
- Dillon, R.L., Marcotte, R., Hennessy, B.T., Woodgett, J.R., Mills, G.B., and Muller, W.J. (2009). Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. *Cancer Res.* 69, 5057–5064.
- Ding, Q., He, X., Hsu, J.M., Xia, W., Chen, C.T., Li, L.Y., Lee, D.F., Liu, J.C., Zhong, Q., Wang, X., and Hung, M.C. (2007). Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. *Mol. Cell Biol.* 27, 4006–4017.
- Ding, L., Biswas, S., Morton, R.E., Smith, J.D., Hay, N., Byzova, T.V., Febbraio, M., and Podrez, E.A. (2012). Akt3 deficiency in macrophages promotes foam cell formation and atherosclerosis in mice. *Cell Metab.* 15, 861–872.
- DiPilato, L.M., Ahmad, F., Harms, M., Seale, P., Manganiello, V., and Birnbaum, M.J. (2015). The Role of PDE3B Phosphorylation in the Inhibition of Lipolysis by Insulin. *Mol. Cell Biol.* 35, 2752–2760.
- Dumaz, N., and Marais, R. (2003). Protein kinase A blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with Ras. *J. Biol. Chem.* 278, 29819–29823.
- Dumble, M., Crouthamel, M.C., Zhang, S.Y., Schaber, M., Levy, D., Robell, K., Liu, Q., Figueroa, D.J., Minthorn, E.A., Seefeld, M.A., et al. (2014). Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. *PLoS ONE* 9, e100880.
- Dummler, B., and Hemmings, B.A. (2007). Physiological roles of PKB/Akt isoforms in development and disease. *Biochem. Soc. Trans.* 35, 231–235.

- Dummler, B., Tschopp, O., Hynx, D., Yang, Z.Z., Dirnhofer, S., and Hemmings, B.A. (2006). Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies. *Mol. Cell Biol.* 26, 8042–8051.
- Düvel, K., Yecies, J.L., Menon, S., Raman, P., Lipovsky, A.I., Souza, A.L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. (2010). Activation of a metabolic gene regulatory network downstream of mTOR complex 1. *Mol. Cell* 39, 171–183.
- Easton, R.M., Cho, H., Roovers, K., Shineman, D.W., Mizrahi, M., Forman, M.S., Lee, V.M., Szabolcs, M., de Jong, R., Oltersdorf, T., et al. (2005). Role for Akt3/protein kinase Bgamma in attainment of normal brain size. *Mol. Cell Biol.* 25, 1869–1878.
- Ebner, M., Lučić, I., Leonard, T.A., and Yudushkin, I. (2017a). PI(3,4,5)P3 Engagement Restricts Akt Activity to Cellular Membranes. *Mol. Cell* 65, 416–431.
- Ebner, M., Sinkovics, B., Szczygiel, M., Ribeiro, D.W., and Yudushkin, I. (2017b). Localization of mTORC2 activity inside cells. *J. Cell Biol.* 216, 343–353.
- Egerman, M.A., and Glass, D.J. (2014). Signaling pathways controlling skeletal muscle mass. *Crit. Rev. Biochem. Mol. Biol.* 49, 59–68.
- Eguez, L., Lee, A., Chavez, J.A., Miinea, C.P., Kane, S., Lienhard, G.E., and McGraw, T.E. (2005). Full intracellular retention of GLUT4 requires AS160 Rab GTPase activating protein. *Cell Metab.* 2, 263–272.
- Emamian, E.S., Hall, D., Birnbaum, M.J., Karayiorgou, M., and Gogos, J.A. (2004). Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. *Nat. Genet.* 36, 131–137.
- Facchinetti, V., Ouyang, W., Wei, H., Soto, N., Lazorchak, A., Gould, C., Lowry, C., Newton, A.C., Mao, Y., Miao, R.Q., et al. (2008). The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. *EMBO J.* 27, 1932–1943.
- Fan, W., Morinaga, H., Kim, J.J., Bae, E., Spann, N.J., Heinz, S., Glass, C.K., and Olefsky, J.M. (2010). FoxO1 regulates Tlr4 inflammatory pathway signaling in macrophages. *EMBO J.* 29, 4223–4236.
- Fan, C.D., Lum, M.A., Xu, C., Black, J.D., and Wang, X. (2013). Ubiquitin-dependent regulation of phospho-AKT dynamics by the ubiquitin E3 ligase, NEDD4-1, in the insulin-like growth factor-1 response. *J. Biol. Chem.* 288, 1674–1684.
- Fedele, C.G., Ooms, L.M., Ho, M., Vieusseux, J., O'Toole, S.A., Millar, E.K., Lopez-Knowles, E., Sriratanana, A., Gurung, R., Baglietto, L., et al. (2010). Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. *Proc. Natl. Acad. Sci. USA* 107, 22231–22236.
- Fernández-Hernando, C., Ackah, E., Yu, J., Suárez, Y., Murata, T., Iwakiri, Y., Prendergast, J., Miao, R.Q., Birnbaum, M.J., and Sessa, W.C. (2007). Loss of Akt1 leads to severe atherosclerosis and occlusive coronary artery disease. *Cell Metab.* 6, 446–457.
- Fernández-Hernando, C., József, L., Jenkins, D., Di Lorenzo, A., and Sessa, W.C. (2009). Absence of Akt1 reduces vascular smooth muscle cell migration and survival and induces features of plaque vulnerability and cardiac dysfunction during atherosclerosis. *Arterioscler. Thromb. Vasc. Biol.* 29, 2033–2040.
- Fonseca, B.D., Smith, E.M., Lee, V.H., MacKintosh, C., and Proud, C.G. (2007). PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. *J. Biol. Chem.* 282, 24514–24524.
- Frame, S., Cohen, P., and Biondi, R.M. (2001). A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. *Mol. Cell* 7, 1321–1327.
- Franke, T.F., Yang, S.I., Chan, T.O., Datta, K., Kazlauskas, A., Morrison, D.K., Kaplan, D.R., and Tsichlis, P.N. (1995). The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. *Cell* 81, 727–736.
- Franke, T.F., Kaplan, D.R., Cantley, L.C., and Tokier, A. (1997). Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. *Science* 275, 665–668.
- Frech, M., Andjelkovic, M., Ingley, E., Reddy, K.K., Falck, J.R., and Hemmings, B.A. (1997). High affinity binding of inositol phosphates and phosphoinositides to the pleckstrin homology domain of RAC/protein kinase B and their influence on kinase activity. *J. Biol. Chem.* 272, 8474–8481.
- Gao, T., Furnari, F., and Newton, A.C. (2005). PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. *Mol. Cell* 18, 13–24.
- Garofalo, R.S., Orena, S.J., Rafidi, K., Torchia, A.J., Stock, J.L., Hildebrandt, A.L., Coskran, T., Black, S.C., Brees, D.J., Wicks, J.R., et al. (2003). Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. *J. Clin. Invest.* 112, 197–208.
- George, S., Rochford, J.J., Wolfrum, C., Gray, S.L., Schinner, S., Wilson, J.C., Soos, M.A., Murgatroyd, P.R., Williams, R.M., Acerini, C.L., et al. (2004). A family with severe insulin resistance and diabetes due to a mutation in AKT2. *Science* 304, 1325–1328.
- Gerriets, V.A., Kishton, R.J., Johnson, M.O., Cohen, S., Siska, P.J., Nichols, A.G., Warmoes, M.O., de Cubas, A.A., MacIver, N.J., Locasale, J.W., et al. (2016). Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression. *Nat. Immunol.* 17, 1459–1466.
- Gewinner, C., Wang, Z.C., Richardson, A., Teruya-Feldstein, J., Etemadmoghadam, D., Bowtell, D., Barretina, J., Lin, W.M., Rameh, L., Salmena, L., et al. (2009). Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. *Cancer Cell* 16, 115–125.
- Griffin, R.J., Moloney, A., Kelliher, M., Johnston, J.A., Ravid, R., Dockery, P., O'Connor, R., and O'Neill, C. (2005). Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. *J. Neurochem.* 93, 105–117.
- Guan, K.L., Figueroa, C., Brtva, T.R., Zhu, T., Taylor, J., Barber, T.D., and Vojtek, A.B. (2000). Negative regulation of the serine/threonine kinase B-Raf by Akt. *J. Biol. Chem.* 275, 27354–27359.
- Guertin, D.A., Stevens, D.M., Thoreen, C.C., Burds, A.A., Kalaany, N.Y., Mofatt, J., Brown, M., Fitzgerald, K.J., and Sabatini, D.M. (2006). Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. *Dev. Cell* 11, 859–871.
- Guilherme, A., Klarlund, J.K., Krystal, G., and Czech, M.P. (1996). Regulation of phosphatidylinositol 3,4,5-trisphosphate 5'-phosphatase activity by insulin. *J. Biol. Chem.* 271, 29533–29536.
- Gulen, M.F., Bulek, K., Xiao, H., Yu, M., Gao, J., Sun, L., Beurel, E., Kaidanovich-Beilin, O., Fox, P.L., DiCorleto, P.E., et al. (2012). Inactivation of the enzyme GSK3 $\alpha$  by the kinase IKKi promotes AKT-mTOR signaling pathway that mediates interleukin-1-induced Th17 cell maintenance. *Immunity* 37, 800–812.
- Guo, H., Gao, M., Lu, Y., Liang, J., Lorenzi, P.L., Bai, S., Hawke, D.H., Li, J., Dogruluk, T., Scott, K.L., et al. (2014). Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules. *Oncogene* 33, 3463–3472.
- Guo, J., Chakraborty, A.A., Liu, P., Gan, W., Zheng, X., Inuzuka, H., Wang, B., Zhang, J., Zhang, L., Yuan, M., et al. (2016). pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner. *Science* 353, 929–932.
- Harrington, L.S., Findlay, G.M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N.R., Cheng, S., Shepherd, P.R., et al. (2004). The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. *J. Cell Biol.* 166, 213–223.
- Hawkins, P.T., and Stephens, L.R. (2016). Emerging evidence of signalling roles for PI(3,4)P2 in Class I and II PI3K-regulated pathways. *Biochem. Soc. Trans.* 44, 307–314.
- Hawley, S.A., Ross, F.A., Gowans, G.J., Tibarewal, P., Leslie, N.R., and Hardie, D.G. (2014). Phosphorylation by Akt within the ST loop of AMPK- $\alpha$ 1 down-regulates its activation in tumour cells. *Biochem. J.* 459, 275–287.
- Hirai, H., Sootome, H., Nakatsuru, Y., Miyama, K., Taguchi, S., Tsujioka, K., Ueno, Y., Hatch, H., Majumder, P.K., Pan, B.S., and Kotani, H. (2010). MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard

- chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. *Mol. Cancer Ther.* 9, 1956–1967.
- Hirsch, E., Katanaev, V.L., Garlanda, C., Azzolino, O., Pirola, L., Silengo, L., Sozzani, S., Mantovani, A., Altruda, F., and Wymann, M.P. (2000). Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. *Science* 287, 1049–1053.
- Holz, M.K., and Blenis, J. (2005). Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. *J. Biol. Chem.* 280, 26089–26093.
- Horman, S., Vertommen, D., Heath, R., Neumann, D., Mouton, V., Woods, A., Schlattner, U., Wallimann, T., Carling, D., Hue, L., and Rider, M.H. (2006). Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase alpha-subunits in heart via hierarchical phosphorylation of Ser485/491. *J. Biol. Chem.* 281, 5335–5340.
- Hou, L., and Klann, E. (2004). Activation of the phosphoinositide 3-kinase-Akt mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression. *J. Neurosci.* 24, 6352–6361.
- Howell, J.J., and Manning, B.D. (2011). mTOR couples cellular nutrient sensing to organismal metabolic homeostasis. *Trends Endocrinol. Metab.* 22, 94–102.
- Hsu, P.P., Kang, S.A., Rameseder, J., Zhang, Y., Ottina, K.A., Lim, D., Peterson, T.R., Choi, Y., Gray, N.S., Yaffe, M.B., et al. (2011). The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. *Science* 332, 1317–1322.
- Huang, J., Dibble, C.C., Matsuzaki, M., and Manning, B.D. (2008). The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. *Mol. Cell Biol.* 28, 4104–4115.
- Hussain, K., Challis, B., Rocha, N., Payne, F., Minic, M., Thompson, A., Daly, A., Scott, C., Harris, J., Smillie, B.J., et al. (2011). An activating mutation of AKT2 and human hypoglycemia. *Science* 334, 474.
- Hutchinson, J.N., Jin, J., Cardiff, R.D., Woodgett, J.R., and Muller, W.J. (2004). Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. *Cancer Res.* 64, 3171–3178.
- Ikenoue, T., Inoki, K., Yang, Q., Zhou, X., and Guan, K.L. (2008). Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. *EMBO J.* 27, 1919–1931.
- Inoki, K., Li, Y., Zhu, T., Wu, J., and Guan, K.L. (2002). TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. *Nat. Cell Biol.* 4, 648–657.
- Irie, H.Y., Pearline, R.V., Grueneberg, D., Hsia, M., Ravichandran, P., Kothari, N., Natesan, S., and Brugge, J.S. (2005). Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. *J. Cell Biol.* 171, 1023–1034.
- Izumiya, Y., Hopkins, T., Morris, C., Sato, K., Zeng, L., Viereck, J., Hamilton, J.A., Ouchi, N., LeBrasseur, N.K., and Walsh, K. (2008). Fast/Glycolytic muscle fiber growth reduces fat mass and improves metabolic parameters in obese mice. *Cell Metab.* 7, 159–172.
- Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S.Y., Huang, Q., Qin, J., and Su, B. (2006). SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. *Cell* 127, 125–137.
- Jagannath, C., Lindsey, D.R., Dhandayuthapani, S., Xu, Y., Hunter, R.L., Jr., and Eissa, N.T. (2009). Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. *Nat. Med.* 15, 267–276.
- James, S.R., Downes, C.P., Gigg, R., Grove, S.J.A., Holmes, A.B., and Alessi, D.R. (1996). Specific binding of the Akt-1 protein kinase to phosphatidylinositol 3,4,5-trisphosphate without subsequent activation. *Biochem. J.* 315, 709–713.
- Jethwa, N., Chung, G.H., Lete, M.G., Alonso, A., Byrne, R.D., Calleja, V., and Larjani, B. (2015). Endomembrane PtdIns(3,4,5)P3 activates the PI3K-Akt pathway. *J. Cell Sci.* 128, 3456–3465.
- Jiang, H., Guo, W., Liang, X., and Rao, Y. (2005). Both the establishment and the maintenance of neuronal polarity require active mechanisms: critical roles of GSK-3beta and its upstream regulators. *Cell* 120, 123–135.
- Jiang, H., Westerterp, M., Wang, C., Zhu, Y., and Ai, D. (2014). Macrophage mTORC1 disruption reduces inflammation and insulin resistance in obese mice. *Diabetologia* 57, 2393–2404.
- Jones, P.F., Jakubowicz, T., Pitossi, F.J., Maurer, F., and Hemmings, B.A. (1991). Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. *Proc. Natl. Acad. Sci. USA* 88, 4171–4175.
- Julien, L.A., Carriere, A., Moreau, J., and Roux, P.P. (2010). mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. *Mol. Cell Biol.* 30, 908–921.
- Juntilla, M.M., Wofford, J.A., Birnbaum, M.J., Rathmell, J.C., and Koretzky, G.A. (2007). Akt1 and Akt2 are required for alphabeta thymocyte survival and differentiation. *Proc. Natl. Acad. Sci. USA* 104, 12105–12110.
- Kaidanovich-Beilin, O., and Woodgett, J.R. (2011). GSK-3: Functional Insights from Cell Biology and Animal Models. *Front. Mol. Neurosci.* 4, 40.
- Keppeler-Noreuil, K.M., Sapp, J.C., Lindhurst, M.J., Parker, V.E., Blumhorst, C., Darling, T., Tosi, L.L., Huson, S.M., Whitehouse, R.W., Jakkula, E., et al. (2014). Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. *Am. J. Med. Genet. A.* 164A, 1713–1733.
- Kerdiles, Y.M., Stone, E.L., Beisner, D.R., McGargill, M.A., Ch'en, I.L., Stockmann, C., Katayama, C.D., and Hedrick, S.M. (2010). Foxo transcription factors control regulatory T cell development and function. *Immunity* 33, 890–904.
- Kidani, Y., Elsaesser, H., Hock, M.B., Vergnes, L., Williams, K.J., Argus, J.P., Marbois, B.N., Komisopoulou, E., Wilson, E.B., Osborne, T.F., et al. (2013). Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity. *Nat. Immunol.* 14, 489–499.
- Kim, M.S., Pak, Y.K., Jang, P.G., Namkoong, C., Choi, Y.S., Won, J.C., Kim, K.S., Kim, S.W., Kim, H.S., Park, J.Y., et al. (2006). Role of hypothalamic Foxo1 in the regulation of food intake and energy homeostasis. *Nat. Neurosci.* 9, 901–906.
- Kim, E.K., Yun, S.J., Ha, J.M., Kim, Y.W., Jin, I.H., Yun, J., Shin, H.K., Song, S.H., Kim, J.H., Lee, J.S., et al. (2011). Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis. *Oncogene* 30, 2954–2963.
- Kitamura, T., Kitamura, Y., Kuroda, S., Hino, Y., Ando, M., Kotani, K., Konishi, H., Matsuzaki, H., Kikkawa, U., Ogawa, W., and Kasuga, M. (1999). Insulin-induced phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serine-threonine kinase Akt. *Mol. Cell Biol.* 19, 6286–6296.
- Klippel, A., Kavanaugh, W.M., Pot, D., and Williams, L.T. (1997). A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain. *Mol. Cell Biol.* 17, 338–344.
- Kohn, A.D., Kovacina, K.S., and Roth, R.A. (1995). Insulin stimulates the kinase activity of RAC-PK, a pleckstrin homology domain containing ser/thr kinase. *EMBO J.* 14, 4288–4295.
- Kops, G.J., de Ruiter, N.D., De Vries-Smits, A.M., Powell, D.R., Bos, J.L., and Burgering, B.M. (1999). Direct control of the Forkhead transcription factor AFX by protein kinase B. *Nature* 398, 630–634.
- Koren, S., DiPilato, L.M., Emmett, M.J., Shearin, A.L., Chu, Q., Monks, B., and Birnbaum, M.J. (2015). The role of mouse Akt2 in insulin-dependent suppression of adipocyte lipolysis in vivo. *Diabetologia* 58, 1063–1070.
- Kovacina, K.S., Park, G.Y., Bae, S.S., Guzzetta, A.W., Schaefer, E., Birnbaum, M.J., and Roth, R.A. (2003). Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. *J. Biol. Chem.* 278, 10189–10194.
- Kumar, A., Lawrence, J.C., Jr., Jung, D.Y., Ko, H.J., Keller, S.R., Kim, J.K., Magnuson, M.A., and Harris, T.E. (2010). Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism. *Diabetes* 59, 1397–1406.

- Kunkel, M.T., Ni, Q., Tsien, R.Y., Zhang, J., and Newton, A.C. (2005). Spatio-temporal dynamics of protein kinase B/Akt signaling revealed by a genetically encoded fluorescent reporter. *J. Biol. Chem.* *280*, 5581–5587.
- Kuo, Y.C., Huang, K.Y., Yang, C.H., Yang, Y.S., Lee, W.Y., and Chiang, C.W. (2008). Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. *J. Biol. Chem.* *283*, 1882–1892.
- Landgraf, K.E., Pilling, C., and Falke, J.J. (2008). Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain. *Biochemistry* *47*, 12260–12269.
- Lapierre, J.M., Eathiraj, S., Vensel, D., Liu, Y., Bull, C.O., Cornell-Kennon, S., Imura, S., Kelleher, E.W., Kizer, D.E., Koerner, S., et al. (2016). Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor. *J. Med. Chem.* *59*, 6455–6469.
- Lauring, J., Cosgrove, D.P., Fontana, S., Gustin, J.P., Konishi, H., Abukhdeir, A.M., Garay, J.P., Mohseni, M., Wang, G.M., Higgins, M.J., et al. (2010). Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations. *Oncogene* *29*, 2337–2345.
- Leavens, K.F., Easton, R.M., Shulman, G.I., Previs, S.F., and Birnbaum, M.J. (2009). Akt2 is required for hepatic lipid accumulation in models of insulin resistance. *Cell Metab.* *10*, 405–418.
- Lee, S.W., Dai, G., Hu, Z., Wang, X., Du, J., and Mitch, W.E. (2004). Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. *J. Am. Soc. Nephrol.* *15*, 1537–1545.
- Lee, M.Y., Luciano, A.K., Ackah, E., Rodriguez-Vita, J., Bancroft, T.A., Eichmann, A., Simons, M., Kyriakides, T.R., Morales-Ruiz, M., and Sessa, W.C. (2014). Endothelial Akt1 mediates angiogenesis by phosphorylating multiple angiogenic substrates. *Proc. Natl. Acad. Sci. USA* *111*, 12865–12870.
- Leto, D., and Saltiel, A.R. (2012). Regulation of glucose transport by insulin: traffic control of GLUT4. *Nat. Rev. Mol. Cell Biol.* *13*, 383–396.
- Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S.I., Puc, J., Milliaris, C., Rodgers, L., McCombie, R., et al. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. *Science* *275*, 1943–1947.
- Li, Z., Jiang, H., Xie, W., Zhang, Z., Smrcka, A.V., and Wu, D. (2000). Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. *Science* *287*, 1046–1049.
- Li, N., Lee, B., Liu, R.J., Banasr, M., Dwyer, J.M., Iwata, M., Li, X.Y., Aghajanian, G., and Duman, R.S. (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. *Science* *329*, 959–964.
- Li, R., Wei, J., Jiang, C., Liu, D., Deng, L., Zhang, K., and Wang, P. (2013). Akt SUMOylation regulates cell proliferation and tumorigenesis. *Cancer Res.* *73*, 5742–5753.
- Li Chew, C., Lunardi, A., Gulluni, F., Ruan, D.T., Chen, M., Salmena, L., Nishino, M., Papa, A., Ng, C., Fung, J., et al. (2015). In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes. *Cancer Discov.* *5*, 740–751.
- Lien, E.C., Lyssiotis, C.A., Juvekar, A., Hu, H., Asara, J.M., Cantley, L.C., and Toker, A. (2016). Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer. *Nat. Cell Biol.* *18*, 572–578.
- Lien, E.C., Dibble, C.C., and Toker, A. (2017). PI3K signaling in cancer: beyond AKT. *Curr. Opin. Cell Biol.* *45*, 62–71.
- Lim, J.H., Jono, H., Komatsu, K., Woo, C.H., Lee, J., Miyata, M., Matsuno, T., Xu, X., Huang, Y., Zhang, W., et al. (2012). CYLD negatively regulates transforming growth factor-beta-signaling via deubiquitinating Akt. *Nat. Commun.* *3*, 771.
- Lin, K., Lin, J., Wu, W.I., Ballard, J., Lee, B.B., Gloor, S.L., Vigers, G.P., Morales, T.H., Friedman, L.S., Skelton, N., and Brandhuber, B.J. (2012). An ATP-site on-off switch that restricts phosphatase accessibility of Akt. *Sci. Signal.* *5*, ra37.
- Lin, J., Sampath, D., Nannini, M.A., Lee, B.B., Degtyarev, M., Oeh, J., Savage, H., Guan, Z., Hong, R., Kassees, R., et al. (2013). Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. *Clin. Cancer Res.* *19*, 1760–1772.
- Lindhurst, M.J., Sapp, J.C., Teer, J.K., Johnston, J.J., Finn, E.M., Peters, K., Turner, J., Cannons, J.L., Bick, D., Blakemore, L., et al. (2011). A mosaic activating mutation in AKT1 associated with the Proteus syndrome. *N. Engl. J. Med.* *365*, 611–619.
- Lipton, J.O., and Sahin, M. (2014). The neurology of mTOR. *Neuron* *84*, 275–291.
- Liu, L., Das, S., Losert, W., and Parent, C.A. (2010). mTORC2 regulates neutrophil chemotaxis in a cAMP- and RhoA-dependent fashion. *Dev. Cell* *19*, 845–857.
- Liu, G., Bi, Y., Wang, R., Shen, B., Zhang, Y., Yang, H., Wang, X., Liu, H., Lu, Y., and Han, F. (2013a). Kinase AKT1 negatively controls neutrophil recruitment and function in mice. *J. Immunol.* *191*, 2680–2690.
- Liu, P., Gan, W., Inuzuka, H., Lazorchak, A.S., Gao, D., Arojo, O., Liu, D., Wan, L., Zhai, B., Yu, Y., et al. (2013b). Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signaling to suppress tumorigenesis. *Nat. Cell Biol.* *15*, 1340–1350.
- Liu, P., Begley, M., Michowski, W., Inuzuka, H., Ginzberg, M., Gao, D., Tsou, P., Gan, W., Papa, A., Kim, B.M., et al. (2014). Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus. *Nature* *508*, 541–545.
- Liu, P., Gan, W., Chin, Y.R., Ogura, K., Guo, J., Zhang, J., Wang, B., Blenis, J., Cantley, L.C., Toker, A., et al. (2015). PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex. *Cancer Discov.* *5*, 1194–1209.
- Lu, Y., Muller, M., Smith, D., Dutta, B., Komurov, K., Iadevaia, S., Ruths, D., Tseng, J.T., Yu, S., Yu, Q., et al. (2011). Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling. *Oncogene* *30*, 4567–4577.
- Lu, M., Wan, M., Leavens, K.F., Chu, Q., Monks, B.R., Fernandez, S., Ahima, R.S., Ueki, K., Kahn, C.R., and Birnbaum, M.J. (2012). Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. *Nat. Med.* *18*, 388–395.
- Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., and Pandolfi, P.P. (2005). Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. *Cell* *121*, 179–193.
- Ma, C.X., Sanchez, C., Gao, F., Crowder, R., Naughton, M., Pluard, T., Creekmore, A., Guo, Z., Hoog, J., Lockhart, A.C., et al. (2016). A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer. *Clin. Cancer Res.* *22*, 2650–2658.
- Macintyre, A.N., Finlay, D., Preston, G., Sinclair, L.V., Waugh, C.M., Tamas, P., Feijoo, C., Okkenhaug, K., and Cantrell, D.A. (2011). Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism. *Immunity* *34*, 224–236.
- Maehama, T., and Dixon, J.E. (1998). The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. *J. Biol. Chem.* *273*, 13375–13378.
- Mancini, M.L., Lien, E.C., and Toker, A. (2016). Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis. *Oncotarget* *7*, 17301–17313.
- Manning, B.D. (2004). Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. *J. Cell Biol.* *167*, 399–403.
- Manning, B.D., and Cantley, L.C. (2007). AKT/PKB signaling: navigating downstream. *Cell* *129*, 1261–1274.
- Manning, B.D., Tee, A.R., Logsdon, M.N., Blenis, J., and Cantley, L.C. (2002). Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. *Mol. Cell* *10*, 151–162.
- Maroulakou, I.G., Oemler, W., Naber, S.P., and Tschlis, P.N. (2007). Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary

- adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. *Cancer Res.* 67, 167–177.
- Matsumoto, M., Pocai, A., Rossetti, L., Depinho, R.A., and Accili, D. (2007). Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. *Cell Metab.* 6, 208–216.
- Maurer, U., Charvet, C., Wagman, A.S., DeJardin, E., and Green, D.R. (2006). Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. *Mol. Cell* 21, 749–760.
- Mayer, I.A., and Arteaga, C.L. (2016). The PI3K/AKT Pathway as a Target for Cancer Treatment. *Annu. Rev. Med.* 67, 11–28.
- McManus, E.J., Collins, B.J., Ashby, P.R., Prescott, A.R., Murray-Tait, V., Armit, L.J., Arthur, J.S., and Alessi, D.R. (2004). The in vivo role of PtdIns(3,4,5)P3 binding to PDK1 PH domain defined by knockin mutation. *EMBO J.* 23, 2071–2082.
- McManus, E.J., Sakamoto, K., Armit, L.J., Ronaldson, L., Shpiro, N., Marquez, R., and Alessi, D.R. (2005). Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. *EMBO J.* 24, 1571–1583.
- Mendoza, M.C., Er, E.E., and Blenis, J. (2011). The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. *Trends Biochem. Sci.* 36, 320–328.
- Menon, S., Dibble, C.C., Talbott, G., Hoxhaj, G., Valvezan, A.J., Takahashi, H., Cantley, L.C., and Manning, B.D. (2014). Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. *Cell* 156, 771–785.
- Mercalli, A., Calavita, I., Dugnani, E., Citro, A., Cantarelli, E., Nano, R., Melzi, R., Maffi, P., Secchi, A., Sordi, V., and Piemonti, L. (2013). Rapamycin unbalances the polarization of human macrophages to M1. *Immunology* 140, 179–190.
- Mihaylova, M.M., and Shaw, R.J. (2011). The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. *Nat. Cell Biol.* 13, 1016–1023.
- Moniz, L.S., Surinova, S., Ghazaly, E., Velasco, L.G., Haider, S., Rodríguez-Prados, J.C., Berenjeno, I.M., Chelala, C., and Vanhaesebroeck, B. (2017). Phosphoproteomic comparison of Ptk3ca and Pten signalling identifies the nucleotidase NT5C as a novel AKT substrate. *Sci. Rep.* 7, 39985.
- Mora, A., Komander, D., van Aalten, D.M., and Alessi, D.R. (2004). PDK1, the master regulator of AGC kinase signal transduction. *Semin. Cell Dev. Biol.* 15, 161–170.
- Morel, C., Carlson, S.M., White, F.M., and Davis, R.J. (2009). Mcl-1 integrates the opposing actions of signaling pathways that mediate survival and apoptosis. *Mol. Cell Biol.* 29, 3845–3852.
- Morrisett, J.D., Abdel-Fattah, G., Hoogeveen, R., Mitchell, E., Ballantyne, C.M., Pownall, H.J., Opekun, A.R., Jaffe, J.S., Oppermann, S., and Kahan, B.D. (2002). Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. *J. Lipid Res.* 43, 1170–1180.
- Mukai, Y., Rikitake, Y., Shiojima, I., Wolfrum, S., Satoh, M., Takeshita, K., Hiroi, Y., Salomone, S., Kim, H.H., Benjamin, L.E., et al. (2006). Decreased vascular lesion formation in mice with inducible endothelial-specific expression of protein kinase Akt. *J. Clin. Invest.* 116, 334–343.
- Muranen, T., Selfors, L.M., Worster, D.T., Iwanicki, M.P., Song, L., Morales, F.C., Gao, S., Mills, G.B., and Brugge, J.S. (2012). Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. *Cancer Cell* 21, 227–239.
- Navé, B.T., Ouwens, M., Withers, D.J., Alessi, D.R., and Shepherd, P.R. (1999). Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. *Biochem. J.* 344, 427–431.
- Ng, Y., Ramm, G., Lopez, J.A., and James, D.E. (2008). Rapid activation of Akt2 is sufficient to stimulate GLUT4 translocation in 3T3-L1 adipocytes. *Cell Metab.* 7, 348–356.
- Nixon, R.A. (2013). The role of autophagy in neurodegenerative disease. *Nat. Med.* 19, 983–997.
- Ohanna, M., Sobering, A.K., Lapointe, T., Lorenzo, L., Praud, C., Petroulakis, E., Sonenberg, N., Kelly, P.A., Sotiropoulos, A., and Pende, M. (2005). Atrophy of S6K1(-/-) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. *Nat. Cell Biol.* 7, 286–294.
- Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., Peskett, E., Pearce, W., Meek, S.E., Salpekar, A., Waterfield, M.D., et al. (2002). Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. *Science* 297, 1031–1034.
- Okuzumi, T., Fiedler, D., Zhang, C., Gray, D.C., Aizenstein, B., Hoffman, R., and Shokat, K.M. (2009). Inhibitor hijacking of Akt activation. *Nat. Chem. Biol.* 5, 484–493.
- Omori, S.A., Cato, M.H., Anzelon-Mills, A., Puri, K.D., Shapiro-Shelef, M., Calame, K., and Rickert, R.C. (2006). Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling. *Immunity* 25, 545–557.
- Ono, H., Shimano, H., Katagiri, H., Yahagi, N., Sakoda, H., Onishi, Y., Anai, M., Ogihara, T., Fujishiro, M., Viana, A.Y., et al. (2003). Hepatic Akt activation induces marked hypoglycemia, hepatomegaly, and hypertriglyceridemia with sterol regulatory element binding protein involvement. *Diabetes* 52, 2905–2913.
- Oshiro, N., Takahashi, R., Yoshino, K., Tanimura, K., Nakashima, A., Eguchi, S., Miyamoto, T., Hara, K., Takehana, K., Avruch, J., et al. (2007). The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. *J. Biol. Chem.* 282, 20329–20339.
- Ouyang, W., Beckett, O., Ma, Q., Paik, J.H., DePinho, R.A., and Li, M.O. (2010). Foxo proteins cooperatively control the differentiation of Foxp3+ regulatory T cells. *Nat. Immunol.* 11, 618–627.
- Padmanabhan, S., Mukhopadhyay, A., Narasimhan, S.D., Tesz, G., Czech, M.P., and Tissenbaum, H.A. (2009). A PP2A regulatory subunit regulates C. elegans insulin/IGF-1 signaling by modulating AKT-1 phosphorylation. *Cell* 136, 939–951.
- Paradis, S., and Ruvkun, G. (1998). *Caenorhabditis elegans* Akt/PKB transduces insulin receptor-like signals from AGE-1 PI3 kinase to the DAF-16 transcription factor. *Genes Dev.* 12, 2488–2498.
- Parikh, C., Janakiraman, V., Wu, W.I., Foo, C.K., Kljavin, N.M., Chaudhuri, S., Stawiski, E., Lee, B., Lin, J., Li, H., et al. (2012). Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers. *Proc. Natl. Acad. Sci. USA* 109, 19368–19373.
- Parker, P.J., Caudwell, F.B., and Cohen, P. (1983). Glycogen synthase from rabbit skeletal muscle; effect of insulin on the state of phosphorylation of the seven phosphoserine residues in vivo. *Eur. J. Biochem.* 130, 227–234.
- Parsons, M.J., Jones, R.G., Tsao, M.S., Odermatt, B., Ohashi, P.S., and Woodgett, J.R. (2001). Expression of active protein kinase B in T cells perturbs both T and B cell homeostasis and promotes inflammation. *J. Immunol.* 167, 42–48.
- Phung, T.L., Ziv, K., Dabydeen, D., Eyiah-Mensah, G., Riveros, M., Perruzzi, C., Sun, J., Monahan-Earley, R.A., Shiojima, I., Nagy, J.A., et al. (2006). Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. *Cancer Cell* 10, 159–170.
- Poduri, A., Evrony, G.D., Cai, X., Elhosary, P.C., Beroukhi, R., Lehtinen, M.K., Hills, L.B., Heinzen, E.L., Hill, A., Hill, R.S., et al. (2012). Somatic activation of AKT3 causes hemispheric developmental brain malformations. *Neuron* 74, 41–48.
- Pollizzi, K.N., Patel, C.H., Sun, I.H., Oh, M.H., Waickman, A.T., Wen, J., Delgoffe, G.M., and Powell, J.D. (2015). mTORC1 and mTORC2 selectively regulate CD8+ T cell differentiation. *J. Clin. Invest.* 125, 2090–2108.
- Polter, A., Beurel, E., Yang, S., Garner, R., Song, L., Miller, C.A., Sweatt, J.D., McMahon, L., Bartolucci, A.A., Li, X., and Jope, R.S. (2010). Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. *Neuropsychopharmacology* 35, 1761–1774.
- Porstmann, T., Santos, C.R., Griffiths, B., Cully, M., Wu, M., Leever, S., Griffiths, J.R., Chung, Y.L., and Schulze, A. (2008). SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. *Cell Metab.* 8, 224–236.

- Potter, C.J., Pedraza, L.G., and Xu, T. (2002). Akt regulates growth by directly phosphorylating Tsc2. *Nat. Cell Biol.* **4**, 658–665.
- Puigserver, P., Rhee, J., Donovan, J., Walkey, C.J., Yoon, J.C., Oriente, F., Kitamura, Y., Altomonte, J., Dong, H., Accili, D., and Spiegelman, B.M. (2003). Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. *Nature* **423**, 550–555.
- Ramm, G., Larance, M., Guilhaus, M., and James, D.E. (2006). A role for 14-3-3 in insulin-stimulated GLUT4 translocation through its interaction with the Rab-GAP AS160. *J. Biol. Chem.* **281**, 29174–29180.
- Rhodes, N., Heerding, D.A., Duckett, D.R., Eberwein, D.J., Knick, V.B., Lansing, T.J., McConnell, R.T., Gilmer, T.M., Zhang, S.Y., Robell, K., et al. (2008). Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. *Cancer Res.* **68**, 2366–2374.
- Risso, G., Blaustein, M., Pozzi, B., Mammi, P., and Srebrow, A. (2015). Akt/PKB: one kinase, many modifications. *Biochem. J.* **468**, 203–214.
- Roberts, M.S., Woods, A.J., Dale, T.C., Van Der Sluijs, P., and Norman, J.C. (2004). Protein kinase B/Akt acts via glycogen synthase kinase 3 to regulate recycling of alpha v beta 3 and alpha 5 beta 1 integrins. *Mol. Cell. Biol.* **24**, 1505–1515.
- Rodriguez-Viciano, P., Warne, P.H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M.J., Waterfield, M.D., and Downward, J. (1994). Phosphatidylinositol-3-OH kinase as a direct target of Ras. *Nature* **370**, 527–532.
- Rodrik-Outmezguine, V.S., Chandarlapaty, S., Pagano, N.C., Poulikakos, P.I., Scaltriti, M., Moskatel, E., Baselga, J., Guichard, S., and Rosen, N. (2011). mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. *Cancer Discov.* **1**, 248–259.
- Romeo, Y., Zhang, X., and Roux, P.P. (2012). Regulation and function of the RSK family of protein kinases. *Biochem. J.* **441**, 553–569.
- Rommel, C., Clarke, B.A., Zimmermann, S., Nuñez, L., Rossman, R., Reid, K., Moelling, K., Yancopoulos, G.D., and Glass, D.J. (1999). Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. *Science* **286**, 1738–1741.
- Rommel, C., Bodine, S.C., Clarke, B.A., Rossman, R., Nunez, L., Stitt, T.N., Yancopoulos, G.D., and Glass, D.J. (2001). Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. *Nat. Cell Biol.* **3**, 1009–1013.
- Rosner, M., Siegel, N., Valli, A., Fuchs, C., and Hengstschläger, M. (2010). mTOR phosphorylated at S2448 binds to raptor and rictor. *Amino Acids* **38**, 223–228.
- Roux, P.P., Ballif, B.A., Anjum, R., Gygi, S.P., and Blenis, J. (2004). Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. *Proc. Natl. Acad. Sci. USA* **101**, 13489–13494.
- Rudolph, M., Anzeneder, T., Schulz, A., Beckmann, G., Byrne, A.T., Jeffers, M., Pena, C., Politz, O., Köchert, K., Vonk, R., and Reischl, J. (2016). AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection. *BMC Cancer* **16**, 622.
- Rylatt, D.B., Aitken, A., Bilham, T., Condon, G.D., Embi, N., and Cohen, P. (1980). Glycogen synthase from rabbit skeletal muscle. Amino acid sequence at the sites phosphorylated by glycogen synthase kinase-3, and extension of the N-terminal sequence containing the site phosphorylated by phosphorylase kinase. *Eur. J. Biochem.* **107**, 529–537.
- Salhia, B., Van Cott, C., Tegeler, T., Polpitiya, A., Duquette, R.A., Gale, M., Hostteter, G., Petritis, K., and Carpten, J. (2012). Differential effects of AKT1 (p.E17K) expression on human mammary luminal epithelial and myoepithelial cells. *Hum. Mutat.* **33**, 1216–1227.
- Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S.M., Riggins, G.J., et al. (2004). High frequency of mutations of the PIK3CA gene in human cancers. *Science* **304**, 554.
- Sancak, Y., Thoreen, C.C., Peterson, T.R., Lindquist, R.A., Kang, S.A., Spooner, E., Carr, S.A., and Sabatini, D.M. (2007). PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. *Mol. Cell* **25**, 903–915.
- Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S.H., and Goldberg, A.L. (2004). Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. *Cell* **117**, 399–412.
- Sanidas, I., Polyarchou, C., Hatziaepostolou, M., Ezell, S.A., Kottakis, F., Hu, L., Guo, A., Xie, J., Comb, M.J., Iliopoulos, D., and Tsiichlis, P.N. (2014). Phosphoproteomics screen reveals akt isoform-specific signals linking RNA processing to lung cancer. *Mol. Cell* **53**, 577–590.
- Sano, H., Kane, S., Sano, E., Miinea, C.P., Asara, J.M., Lane, W.S., Garner, C.W., and Lienhard, G.E. (2003). Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. *J. Biol. Chem.* **278**, 14599–14602.
- Sarbassov, D.D., Guertin, D.A., Ali, S.M., and Sabatini, D.M. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. *Science* **307**, 1098–1101.
- Saura, C., Roda, D., Roselló, S., Oliveira, M., Macarulla, T., Pérez-Fidalgo, J.A., Morales-Barrera, R., Sanchis-García, J.M., Musib, L., Budha, N., et al. (2017). A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. *Cancer Discov.* **7**, 102–113.
- Saxton, R.A., and Sabatini, D.M. (2017). mTOR Signaling in Growth, Metabolism, and Disease. *Cell* **168**, 960–976.
- Sears, R., Nuckolls, F., Haura, E., Taya, Y., Tamai, K., and Nevins, J.R. (2000). Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. *Genes Dev.* **14**, 2501–2514.
- Sekulic, A., Hudson, C.C., Homme, J.L., Yin, P., Otterness, D.M., Karnitz, L.M., and Abraham, R.T. (2000). A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. *Cancer Res.* **60**, 3504–3513.
- Shah, O.J., and Hunter, T. (2006). Turnover of the active fraction of IRS1 involves raptor-mTOR- and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis. *Mol. Cell. Biol.* **26**, 6425–6434.
- Shen, C.H., Yuan, P., Perez-Lorenzo, R., Zhang, Y., Lee, S.X., Ou, Y., Asara, J.M., Cantley, L.C., and Zheng, B. (2013). Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation. *Mol. Cell* **52**, 161–172.
- Shi, L.Z., Wang, R., Huang, G., Vogel, P., Neale, G., Green, D.R., and Chi, H. (2011). HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. *J. Exp. Med.* **208**, 1367–1376.
- Siddiqui, N., and Sonenberg, N. (2015). Signalling to eIF4E in cancer. *Biochem. Soc. Trans.* **43**, 763–772.
- So, L., and Fruman, D.A. (2012). PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. *Biochem. J.* **442**, 465–481.
- Soliman, G.A., Acosta-Jaquez, H.A., and Fingar, D.C. (2010). mTORC1 inhibition via rapamycin promotes triacylglycerol lipolysis and release of free fatty acids in 3T3-L1 adipocytes. *Lipids* **45**, 1089–1100.
- Sommer, E.M., Dry, H., Cross, D., Guichard, S., Davies, B.R., and Alessi, D.R. (2013). Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors. *Biochem. J.* **452**, 499–508.
- Staal, S.P. (1987). Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. *Proc. Natl. Acad. Sci. USA* **84**, 5034–5037.
- Steck, P.A., Pershouse, M.A., Jasser, S.A., Yung, W.K., Lin, H., Ligon, A.H., Langford, L.A., Baumgard, M.L., Hattier, T., Davis, T., et al. (1997). Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. *Nat. Genet.* **15**, 356–362.
- Stephens, P.J., Tarpey, P.S., Davies, H., Van Loo, P., Greenman, C., Wedge, D.C., Nik-Zainal, S., Martin, S., Varela, I., Bignell, G.R., et al.; Oslo Breast Cancer Consortium (OSBREAC) (2012). The landscape of cancer genes and mutational processes in breast cancer. *Nature* **486**, 400–404.



- Stitt, T.N., Drujan, D., Clarke, B.A., Panaro, F., Timofeyeva, Y., Kline, W.O., Gonzalez, M., Yancopoulos, G.D., and Glass, D.J. (2004). The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. *Mol. Cell* *14*, 395–403.
- Stokoe, D., Stephens, L.R., Copeland, T., Gaffney, P.R., Reese, C.B., Painter, G.F., Holmes, A.B., McCormick, F., and Hawkins, P.T. (1997). Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. *Science* *277*, 567–570.
- Sundaresan, N.R., Pillai, V.B., Wolfgeher, D., Samant, S., Vasudevan, P., Parakkh, V., Raghuraman, H., Cunningham, J.M., Gupta, M., and Gupta, M.P. (2011). The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. *Sci. Signal.* *4*, ra46.
- Suzuki, A., Yamaguchi, M.T., Ohteki, T., Sasaki, T., Kaisho, T., Kimura, Y., Yoshida, R., Wakeham, A., Higuchi, T., Fukumoto, M., et al. (2001). T cell-specific loss of Pten leads to defects in central and peripheral tolerance. *Immunity* *14*, 523–534.
- Tang, S.J., Reis, G., Kang, H., Gingras, A.C., Sonenberg, N., and Schuman, E.M. (2002). A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. *Proc. Natl. Acad. Sci. USA* *99*, 467–472.
- Tang, W., Zhang, Y., Xu, W., Harden, T.K., Sondek, J., Sun, L., Li, L., and Wu, D. (2011). A PLC $\beta$ /PI3K $\gamma$ -GSK3 signaling pathway regulates cofilin phosphatase slingshot2 and neutrophil polarization and chemotaxis. *Dev. Cell* *21*, 1038–1050.
- Tang, H., Inoki, K., Lee, M., Wright, E., Khuong, A., Khuong, A., Sugiarto, S., Garner, M., Paik, J., DePinho, R.A., et al. (2014). mTORC1 promotes denervation-induced muscle atrophy through a mechanism involving the activation of FoxO and E3 ubiquitin ligases. *Sci. Signal.* *7*, ra18.
- ter Haar, E., Coll, J.T., Austen, D.A., Hsiao, H.M., Swenson, L., and Jain, J. (2001). Structure of GSK3 $\beta$  reveals a primed phosphorylation mechanism. *Nat. Struct. Biol.* *8*, 593–596.
- Tschopp, O., Yang, Z.Z., Brodbeck, D., Dummler, B.A., Hemmings-Mieszczyk, M., Watanabe, T., Michaelis, T., Frahm, J., and Hemmings, B.A. (2005). Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis. *Development* *132*, 2943–2954.
- Tzatsos, A., and Kandror, K.V. (2006). Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via rapTOR-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. *Mol. Cell Biol.* *26*, 63–76.
- Um, S.H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P.R., Kozma, S.C., Auwerx, J., and Thomas, G. (2004). Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. *Nature* *431*, 200–205.
- van der Vos, K.E., and Coffer, P.J. (2011). The extending network of FOXO transcriptional target genes. *Antioxid. Redox Signal.* *14*, 579–592.
- Vander Haar, E., Lee, S.I., Bandhakavi, S., Griffin, T.J., and Kim, D.H. (2007). Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. *Nat. Cell Biol.* *9*, 316–323.
- Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., and Bilanges, B. (2010). The emerging mechanisms of isoform-specific PI3K signalling. *Nat. Rev. Mol. Cell Biol.* *11*, 329–341.
- Vasudevan, K.M., Barbie, D.A., Davies, M.A., Rabinovsky, R., McNear, C.J., Kim, J.J., Hennessy, B.T., Tseng, H., Pochanard, P., Kim, S.Y., et al. (2009). AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. *Cancer Cell* *16*, 21–32.
- Vivanco, I., Chen, Z.C., Tanos, B., Oldrini, B., Hsieh, W.Y., Yannuzzi, N., Campos, C., and Mellinghoff, I.K. (2014). A kinase-independent function of AKT promotes cancer cell survival. *eLife* *3*, e03751.
- Wan, M., Leavens, K.F., Hunter, R.W., Koren, S., von Wilamowitz-Moellendorff, A., Lu, M., Satapati, S., Chu, Q., Sakamoto, K., Burgess, S.C., and Birnbaum, M.J. (2013). A noncanonical, GSK3-independent pathway controls postprandial hepatic glycogen deposition. *Cell Metab.* *18*, 99–105.
- Wang, S., Huang, X., Sun, D., Xin, X., Pan, Q., Peng, S., Liang, Z., Luo, C., Yang, Y., Jiang, H., et al. (2012). Extensive crosstalk between O-GlcNAcylation and phosphorylation regulates Akt signaling. *PLoS ONE* *7*, e37427.
- Wang, Y., Viscarra, J., Kim, S.J., and Sul, H.S. (2015). Transcriptional regulation of hepatic lipogenesis. *Nat. Rev. Mol. Cell Biol.* *16*, 678–689.
- Wani, R., Qian, J., Yin, L., Bechtold, E., King, S.B., Poole, L.B., Paek, E., Tsang, A.W., and Furdul, C.M. (2011). Isoform-specific regulation of Akt by PDGF-induced reactive oxygen species. *Proc. Natl. Acad. Sci. USA* *108*, 10550–10555.
- Webb, A.E., and Brunet, A. (2014). FOXO transcription factors: key regulators of cellular quality control. *Trends Biochem. Sci.* *39*, 159–169.
- Weichhart, T., Hengstschläger, M., and Linke, M. (2015). Regulation of innate immune cell function by mTOR. *Nat. Rev. Immunol.* *15*, 599–614.
- Welcker, M., Orian, A., Jin, J., Grim, J.E., Harper, J.W., Eisenman, R.N., and Clurman, B.E. (2004). The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. *Proc. Natl. Acad. Sci. USA* *101*, 9085–9090.
- Wisinski, K.B., Tevaarwerk, A.J., Burkard, M.E., Rampurwala, M., Eickhoff, J., Bell, M.C., Kolesar, J.M., Flynn, C., and Liu, G. (2016). Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. *Clin. Cancer Res.* *22*, 2659–2667.
- Xu, P.Z., Chen, M.L., Jeon, S.M., Peng, X.D., and Hay, N. (2012). The effect Akt2 deletion on tumor development in Pten(+/-) mice. *Oncogene* *31*, 518–526.
- Yang, J., Cron, P., Good, V.M., Thompson, V., Hemmings, B.A., and Barford, D. (2002). Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. *Nat. Struct. Biol.* *9*, 940–944.
- Yang, W.L., Wang, J., Chan, C.H., Lee, S.W., Campos, A.D., Lamothe, B., Hur, L., Grabner, B.C., Lin, X., Darnay, B.G., and Lin, H.K. (2009). The E3 ligase TRAF6 regulates Akt ubiquitination and activation. *Science* *325*, 1134–1138.
- Yi, K.H., and Lauring, J. (2016). Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity. *Oncotarget* *7*, 4241–4251.
- Yoshimura, T., Kawano, Y., Arimura, N., Kawabata, S., Kikuchi, A., and Kaibuchi, K. (2005). GSK-3 $\beta$  regulates phosphorylation of CRMP-2 and neuronal polarity. *Cell* *120*, 137–149.
- You, J.S., Anderson, G.B., Dooley, M.S., and Hornberger, T.A. (2015). The role of mTOR signaling in the regulation of protein synthesis and muscle mass during immobilization in mice. *Dis. Model. Mech.* *8*, 1059–1069.
- Yu, Y., Yoon, S.O., Poulogiannis, G., Yang, Q., Ma, X.M., Villén, J., Kubica, N., Hoffman, G.R., Cantley, L.C., Gygi, S.P., and Blenis, J. (2011). Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. *Science* *332*, 1322–1326.
- Yu, Y., Savage, R.E., Eathiraj, S., Meade, J., Wick, M.J., Hall, T., Abbadessa, G., and Schwartz, B. (2015). Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092. *PLoS ONE* *10*, e0140479.
- Zhu, L., Yang, T., Li, L., Sun, L., Hou, Y., Hu, X., Zhang, L., Tian, H., Zhao, Q., Peng, J., et al. (2014). TSC1 controls macrophage polarization to prevent inflammatory disease. *Nat. Commun.* *5*, 4696.
- Zhuang, G., Yu, K., Jiang, Z., Chung, A., Yao, J., Ha, C., Toy, K., Soriano, R., Haley, B., Blackwood, E., et al. (2013). Phosphoproteomic analysis implicates the mTORC2-FoxO1 axis in VEGF signaling and feedback activation of receptor tyrosine kinases. *Sci. Signal.* *6*, ra25.
- Zimmermann, S., and Moelling, K. (1999). Phosphorylation and regulation of Raf by Akt (protein kinase B). *Science* *286*, 1741–1744.